U.S. patent application number 16/661671 was filed with the patent office on 2020-04-09 for fgfr/pd-1 combination therapy for the treatment of cancer.
This patent application is currently assigned to ASTEX THERAPEUTICS LTD. The applicant listed for this patent is ASTEX THERAPEUTICS LTD. Invention is credited to Jayaprakash KARKERA, Matthew V. LORENZI, Suso Jesus PLATERO, Raluca VERONA.
Application Number | 20200108141 16/661671 |
Document ID | / |
Family ID | 56134542 |
Filed Date | 2020-04-09 |
![](/patent/app/20200108141/US20200108141A1-20200409-C00001.png)
![](/patent/app/20200108141/US20200108141A1-20200409-C00002.png)
![](/patent/app/20200108141/US20200108141A1-20200409-C00003.png)
![](/patent/app/20200108141/US20200108141A1-20200409-C00004.png)
![](/patent/app/20200108141/US20200108141A1-20200409-D00001.png)
![](/patent/app/20200108141/US20200108141A1-20200409-D00002.png)
![](/patent/app/20200108141/US20200108141A1-20200409-D00003.png)
![](/patent/app/20200108141/US20200108141A1-20200409-D00004.png)
![](/patent/app/20200108141/US20200108141A1-20200409-D00005.png)
![](/patent/app/20200108141/US20200108141A1-20200409-P00001.png)
![](/patent/app/20200108141/US20200108141A1-20200409-P00002.png)
United States Patent
Application |
20200108141 |
Kind Code |
A1 |
KARKERA; Jayaprakash ; et
al. |
April 9, 2020 |
FGFR/PD-1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER
Abstract
Provided herein are combination therapies for the treatment of
cancer. In particular, the disclosed methods are directed to
treatment of cancer in a patient comprising administering an
antibody that blocks the interaction between PD-1 and PD-L1 and an
FGFR inhibitor, wherein the antibody that blocks the interaction
between PD-1 and PD-L1 and the FGFR inhibitor are administered if
one or more FGFR variants are present in a biological sample from
the patient.
Inventors: |
KARKERA; Jayaprakash;
(Germantown, MD) ; PLATERO; Suso Jesus;
(Washington Crossing, PA) ; VERONA; Raluca;
(Swarthmore, PA) ; LORENZI; Matthew V.;
(Philadelphia, PA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
ASTEX THERAPEUTICS LTD |
CAMBRIDGE |
|
GB |
|
|
Assignee: |
ASTEX THERAPEUTICS LTD
CAMBRIDGE
GB
|
Family ID: |
56134542 |
Appl. No.: |
16/661671 |
Filed: |
October 23, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15079136 |
Mar 24, 2016 |
10478494 |
|
|
16661671 |
|
|
|
|
62142569 |
Apr 3, 2015 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 35/00 20180101;
C12Q 1/6886 20130101; C07K 16/2818 20130101; A61K 39/3955 20130101;
C12Q 2600/158 20130101; A61K 31/498 20130101; G01N 33/57492
20130101; A61P 43/00 20180101; A61K 45/06 20130101; G01N 2333/70596
20130101; G01N 2800/52 20130101; A61K 31/498 20130101; A61K 2300/00
20130101; A61K 39/3955 20130101; A61K 2300/00 20130101 |
International
Class: |
A61K 39/395 20060101
A61K039/395; A61K 31/498 20060101 A61K031/498; G01N 33/574 20060101
G01N033/574; C12Q 1/6886 20060101 C12Q001/6886; C07K 16/28 20060101
C07K016/28; A61K 45/06 20060101 A61K045/06 |
Claims
1. A method of treating cancer in a patient, comprising:
administering to the patient a pharmaceutically effective amount of
an antibody that blocks the interaction between PD-1 and PD-L1 and
a pharmaceutically effective amount of an FGFR inhibitor, wherein
the antibody that blocks the interaction between PD-1 and PD-L1 and
the FGFR inhibitor are administered if one or more FGFR variants
are present in a biological sample from the patient.
2. The method of claim 1, further comprising evaluating the
presence of one or more FGFR variants in the biological sample
before the administering step.
3. The method of claim 1, further comprising evaluating PD-L1
expression in a biological sample.
4. The method of claim 3, wherein the biological sample for the one
or more FGFR variants and the PD-L1 is the same biological
sample.
5. The method of claim 3, wherein the biological sample for the one
or more FGFR variants is different from the biological sample for
PD-L1 expression.
6. The method of claim 1, wherein the biological sample is blood,
lymph fluid, bone marrow, a solid tumor sample, or any combination
thereof.
7. The method of claim 1, wherein the administering step is
performed if PD-L1 expression is low in the biological sample.
8. The method of claim 1, wherein the cancer is lung cancer,
bladder cancer, gastric cancer, breast cancer, ovarian cancer, head
and neck cancer, esophageal cancer, glioblastoma, or any
combination thereof.
9. The method of claim 8, wherein the lung cancer is non-small cell
lung cancer (NSCLC) adenocarcinoma, NSCLC squamous cell carcinoma,
small cell lung cancer, or any combination thereof.
10. The method of claim 1, wherein the one or more FGFR variants
comprise an FGFR mutation, an FGFR amplification, an FGFR fusion
gene, or a combination thereof.
11. The method of claim 10, wherein the FGFR fusion gene is
FGFR2:AFF3; FGFR2:BICC1; FGFR2:CASP7; FGFR2:CCDC6; FGFR2:OFD1;
FGFR3:BAIAP2L1; FGFR3:TACC3-Intron; FGFR3:TACC3V1; FGFR3:TACC3V3;
or a combination thereof.
12. The method of claim 1, wherein the antibody that blocks the
interaction between PD-1 and PD-L1 is an anti-PD-1 antibody, an
anti-PD-L1 antibody, or a combination thereof.
13. The method of claim 1, wherein the FGFR inhibitor is the
compound of formula (I): ##STR00003## or a pharmaceutically
acceptable salt thereof.
14. A method of treating cancer in a patient comprising:
administering to the patient a pharmaceutically effective amount of
an antibody that blocks the interaction between PD-1 and PD-L1;
monitoring the efficacy of the antibody; and if the antibody is not
efficacious, evaluating a biological sample from the patient for a
presence of one or more FGFR variants; and administering to the
patient a pharmaceutically effective amount of an FGFR inhibitor if
the one or more FGFR variants are present in the sample.
15. The method of claim 14, wherein the evaluating step further
comprises measuring an expression level of PD-L1 in a biological
sample and wherein the second administering step comprises
administering the FGFR inhibitor if the expression level of PD-L1
is low.
16. The method of claim 15, wherein the biological sample for the
one or more FGFR variants and the PD-L1 is the same biological
sample.
17. The method of claim 15, wherein the biological sample for the
one or more FGFR variants is different from the biological sample
for PD-L1 expression.
18. (canceled)
19. The method of claim 16, wherein the cancer is lung cancer,
bladder cancer, gastric cancer, breast cancer, ovarian cancer, head
and neck cancer, esophageal cancer, glioblastoma, or any
combination thereof.
20. The method of claim 19, wherein the lung cancer is non-small
cell lung cancer (NSCLC) adenocarcinoma, NSCLC squamous cell
carcinoma, small cell lung cancer, or any combination thereof.
21-23. (canceled)
24. The method of claim 16, wherein the FGFR inhibitor is the
compound of formula (I): ##STR00004## or a pharmaceutically
acceptable salt thereof.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 15/079,136, which was filed on Mar. 24, 2016
and claims priority to U.S. Provisional Application No. 62/142,569,
filed on Apr. 3, 2015. The entire contents of the prior
applications are hereby incorporated by reference herein.
SEQUENCE LISTING
[0002] The instant application contains a Sequence Listing which
has been submitted electronically in ASCII format and is hereby
incorporated by reference in its entirety. Said ASCII copy, created
on Mar. 22, 2016, is named PRD3366USNP_SL.txt (H1594748) and is
53,086 bytes in size.
TECHNICAL FIELD
[0003] Provided herein are combination therapies for the treatment
of cancer. In particular, the disclosed methods are directed to
treatment of cancer in a patient comprising administering an
antibody that blocks the interaction between PD-1 and PD-L1 and a
fibroblast growth factor receptor (FGFR) inhibitor.
BACKGROUND
[0004] For cancer patients failing the main therapeutic option
(front-line therapy) for that cancer type, there is often no
accepted standard of care for second and subsequent-line therapy,
unless a particular genetic abnormality is identified and a
specific therapy is available. Fibroblast growth factor receptors
(FGFRs) are a family of receptor tyrosine kinases involved in
regulating cell survival, proliferation, migration and
differentiation. FGFR alterations have been observed in some
cancers. To date, there are no approved therapies that are
efficacious in patients with FGFR alterations.
SUMMARY
[0005] Disclosed herein are methods of using a combination therapy
that comprises an antibody that blocks the interaction between PD-1
and PD-L1 and an FGFR inhibitor to treat cancer in a patient. In
some embodiments, the methods comprise administering to a patient a
pharmaceutically effective amount of an antibody that blocks the
interaction between PD-1 and PD-L1 and a pharmaceutically effective
amount of an FGFR inhibitor, wherein the antibody that blocks the
interaction between PD-1 and PD-L1 and the FGFR inhibitor are
administered if one or more FGFR variants are present in a
biological sample from the patient.
[0006] In other embodiments, the methods of treating cancer in a
patient comprise: administering to the patient a pharmaceutically
effective amount of an antibody that blocks the interaction between
PD-1 and PD-L1; monitoring the efficacy of the antibody; and, if
the antibody is not efficacious, evaluating a biological sample
from the patient for a presence of one or more FGFR variants and
administering to the patient a pharmaceutically effective amount of
an FGFR inhibitor if the one or more FGFR variants are present in
the sample.
[0007] Also, disclosed herein are uses of an antibody that blocks
the interaction between PD-1 and PD-L1 and an FGFR inhibitor for
the manufacture of a medicament for the treatment of cancer, in
particular for the treatment of cancer in a patient wherein one or
more FGFR variants are present in a biological sample from the
patient. In some embodiments, the medicament contains a
pharmaceutically effective amount of an antibody that blocks the
interaction between PD-1 and PD-L1 and a pharmaceutically effective
amount of an FGFR inhibitor, wherein the medicament is used in a
patient wherein one or more FGFR variants are present in a
biological sample from the patient.
[0008] Also disclosed herein are combinations of an antibody that
blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor
for use in the treatment of cancer, in particular for use in the
treatment of cancer in a patient wherein one or more FGFR variants
are present in a biological sample from the patient. In some
embodiments, the combination comprises a pharmaceutically effective
amount of an antibody that blocks the interaction between PD-1 and
PD-L1 and a pharmaceutically effective amount of an FGFR inhibitor
for use in the treatment of cancer in a patient wherein one or more
FGFR variants are present in a biological sample from the patient.
In other embodiments, the combination for treating cancer comprises
administration of a pharmaceutically effective amount of an
antibody that blocks the interaction between PD-1 and PD-L1;
monitoring the efficacy of the antibody; and, if the antibody is
not efficacious, evaluating a biological sample from the patient
for a presence of one or more FGFR variants, followed by
administration to the patient a pharmaceutically effective amount
of an FGFR inhibitor if the one or more FGFR variants are present
in the sample.
BRIEF DESCRIPTION OF THE DRAWINGS
[0009] The summary, as well as the following detailed description,
is further understood when read in conjunction with the appended
drawings. For the purpose of illustrating the disclosed methods,
there are shown in the drawings exemplary embodiments of the
methods; however, the methods are not limited to the specific
embodiments disclosed. In the drawings:
[0010] FIG. 1 illustrates PD-L1 expression in a 120 lung cancer
samples set by histology and FGFR mutant and amplification status.
PD-L1 H-scores (Y-axis) were plotted for NSCLC adenocarcinoma
(left), small cell lung cancer (middle), and NSCLC squamous
(right). The FGFR mutation and/or amplification status versus the
PD-L1 staining for each of the 120 samples is shown. Mutation--an
FGFR mutation was identified, but no amplification or fusion was
detected; No FGFR Alteration--no mutation, amplification, or fusion
was detected; Amplification--an FGFR gene amplification was
identified, but no FGFR mutation or fusion was detected;
Mutation+Amp--samples were positive for both FGFR mutation and gene
amplification, but no fusion was detected; Not Tested--IHC for
PD-L1 was performed, but sample was not tested on Foundation
Medicine panel.
[0011] FIG. 2 illustrates PD-L1 expression in an 80 non-small-cell
lung carcinoma (NSCLC) sample set by FGFR fusion status by NSCLC
histology. PD-L1 H-scores (Y-axis) were plotted for NSCLC
adenocarcinoma (left), and NSCLC squamous (right). The FGFR fusion
status versus the PD-L1 staining for each of the 80 samples is
shown. Fusion Positive--an FGFR fusion was detected; Fusion
Wild-Type--no FGFR fusion was detected; Not Tested--insufficient
sample for testing or quality control (QC) failure.
[0012] FIG. 3 illustrates the effect of JNJ42756493 on immune cell
viability. Normal donor peripheral blood mononuclear cells (PBMCs),
either unstimulated or stimulated with anti-CD3 antibodies, were
treated with increasing concentrations of JNJ42756493 (0.0000077,
0.000023, 0.000070, 0.00021, 0.00063, 0.00188, 0.00565, 0.01694,
0.051, 0.152, 0.457, 1.372, 4.115, 12.346, 37.037, 111.111,
333.333, and 1000 nM). On days 1, 2, 5 and 6 after plating, cell
viability was assessed by CellTiter-Glo (Promega).
[0013] FIG. 4 illustrates the effect of JNJ42756493 on IFN-.gamma.
levels induced by anti-PD-1 antibodies in a Mixed Lymphocyte
Reaction (MLR) Assay. Cultures of CD4.sup.+ T and allogeneic
dendritic cells were treated with anti-PD-1 antibodies
(concentrations left to right--30, 10, 3.33, 1.11, 0.37, 0.12 nM).
JNJ42756493 was added at 100, 1, or 0.01 nM alone (concentrations
left to right), together with anti-PD-1 antibodies (100, 1, or 0.01
nM JNJ42756493 together with 30, 10, 3.33, 1.11, 0.37, or 0.12 nM
of anti-PD-1 antibody), or in the presence of isotype control (IC).
5 days after treatment, IFN-.gamma. levels in the supernatant were
measured by Meso Scale Discovery (MSD).
[0014] FIG. 5 illustrates the effect of JNJ42756493 on IFN-.gamma.
levels induced by anti-PD-1 antibodies in a Cytomegalovirus antigen
assay (CMV) Assay. Peripheral blood mononuclear cells (PMBCs) were
stimulated with CMV antigen and treated with anti-PD-1 antibodies
(concentration left to right--30, 10, 3.33, 1.11, 0.37, 0.12 nM) as
indicated. JNJ42756493 was added at 100, 1, or 0.01 nM alone
(concentrations left to right), together with anti-PD-1 antibodies
(100, 1, or 0.01 nM JNJ42756493 together with 30, 10, 3.33, 1.11,
0.37, or 0.12 nM of anti-PD-1 antibody), or in the presence of
isotype control (IC). 6 days after treatment, IFN-.gamma. levels in
the supernatant were measured by MSD.
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
[0015] The disclosed methods may be understood more readily by
reference to the following detailed description taken in connection
with the accompanying figures, which form a part of this
disclosure. It is to be understood that the disclosed methods are
not limited to the specific methods described and/or shown herein,
and that the terminology used herein is for the purpose of
describing particular embodiments by way of example only and is not
intended to be limiting of the claimed methods.
[0016] Unless specifically stated otherwise, any description as to
a possible mechanism or mode of action or reason for improvement is
meant to be illustrative only, and the disclosed methods are not to
be constrained by the correctness or incorrectness of any such
suggested mechanism or mode of action or reason for
improvement.
[0017] Reference to a particular numerical value includes at least
that particular value, unless the context clearly dictates
otherwise. When a range of values is expressed, another embodiment
includes from the one particular value and/or to the other
particular value. Further, reference to values stated in ranges
include each and every value within that range. All ranges are
inclusive and combinable.
[0018] When values are expressed as approximations, by use of the
antecedent "about," it will be understood that the particular value
forms another embodiment.
[0019] The term "about" when used in reference to numerical ranges,
cutoffs, or specific values is used to indicate that the recited
values may vary by up to as much as 10% from the listed value.
Thus, the term "about" is used to encompass variations of +10% or
less, variations of .+-.5% or less, variations of .+-.1% or less,
variations of .+-.0.5% or less, or variations of .+-.0.1% or less
from the specified value.
[0020] It is to be appreciated that certain features of the
disclosed methods which are, for clarity, described herein in the
context of separate embodiments, may also be provided in
combination in a single embodiment. Conversely, various features of
the disclosed methods that are, for brevity, described in the
context of a single embodiment, may also be provided separately or
in any subcombination.
[0021] As used herein, the singular forms "a," "an," and "the"
include the plural.
[0022] The following abbreviations are used throughout the
disclosure: FFPE (formalin-fixed, paraffin-embedded); NSCLC
(non-small-cell lung carcinoma); SCLC (small-cell lung cancer);
FGFR (fibroblast growth factor receptor); PD-1 (programmed cell
death 1); PD-L1 (programmed death-ligand 1); FGFR3:TACC3 (fusion
between genes encoding FGFR3 and transforming acidic coiled-coil
containing protein 3); FGFR3:BAIAP2L1 (fusion between genes
encoding FGFR3 and brain-specific angiogenesis inhibitor
1-associated protein 2-like protein 1); FGFR2:AFF3 (fusion between
genes encoding FGFR2 and AF4/FMR2 family, member 3); FGFR2:BICC1
(fusion between genes encoding FGFR2 and bicaudal C homolog 1);
FGFR2: CASP7 (fusion between genes encoding FGFR2 and caspase 7);
FGFR2:CCDC6 (fusion between genes encoding FGFR2 and coiled-coil
domain containing 6); FGFR2:OFD1 (fusion between genes encoding
FGFR2 and oral-facial-digital syndrome 1).
[0023] The term "antibody" refers to (a) immunoglobulin
polypeptides, i.e., polypeptides of the immunoglobulin family that
contain an antigen binding site that specifically binds to a
specific antigen (e.g., PD-1 or PD-L1), including all
immunoglobulin isotypes (IgG, IgA, IgE, IgM, IgD, and IgY), classes
(e.g. IgG1, IgG2, IgG3, IgG4, IgA1, IgA2), subclasses, and various
monomeric and polymeric forms of each isotype, unless otherwise
specified, and (b) conservatively substituted variants of such
immunoglobulin polypeptides that immunospecifically bind to the
antigen (e.g., PD-1 or PD-L1). Antibodies are generally described
in, for example, Harlow & Lane, Antibodies: A Laboratory Manual
(Cold Spring Harbor Laboratory Press, 1988). Unless otherwise
apparent from the context, reference to an antibody also includes
antibody derivatives as described in more detail below.
[0024] "Antibody fragments" comprise a portion of a full length
antibody, generally the antigen-binding or variable region thereof,
such as Fab, Fab', F(ab').sub.2, and Fv fragments; diabodies;
linear antibodies; single-chain antibody molecules; and
multispecific antibodies formed from antibody fragments. Various
techniques have been developed for the production of antibody
fragments, including proteolytic digestion of antibodies and
recombinant production in host cells; however, other techniques for
the production of antibody fragments will be apparent to the
skilled practitioner. In some embodiments, the antibody fragment of
choice is a single chain Fv fragment (scFv). "Single-chain Fv" or
"scFv" antibody fragments comprise the V.sub.H and V.sub.L domains
of antibody, wherein these domains are present in a single
polypeptide chain. Generally, the Fv polypeptide further comprises
a polypeptide linker between the V.sub.H and V.sub.L domains which
enables the scFv to form the desired structure for antigen binding.
For a review of scFv and other antibody fragments, see James D.
Marks, Antibody Engineering, Chapter 2, Oxford University Press
(1995) (Carl K. Borrebaeck, Ed.).
[0025] An "antibody derivative" means an antibody, as defined
above, that is modified by covalent attachment of a heterologous
molecule such as, e.g., by attachment of a heterologous polypeptide
(e.g., a cytotoxin) or therapeutic agent (e.g., a chemotherapeutic
agent), or by glycosylation, deglycosylation, acetylation or
phosphorylation not normally associated with the antibody, and the
like.
[0026] The term "monoclonal antibody" refers to an antibody that is
derived from a single cell clone, including any eukaryotic or
prokaryotic cell clone, or a phage clone, and not the method by
which it is produced. Thus, the term "monoclonal antibody" is not
limited to antibodies produced through hybridoma technology.
[0027] "Biological sample" refers to any sample from a patient in
which cancerous cells can be obtained and protein expression can be
evaluated and/or RNA can be isolated. Suitable biological samples
include, but are not limited to, blood, lymph fluid, bone marrow,
sputum, a solid tumor sample, or any combination thereof. In some
embodiments, the biological sample can be formalin-fixed
paraffin-embedded tissue (FFPET).
[0028] As used here, "block(s) the interaction" refers to the
ability of an anti-PD-1 antibody or an anti-PD-L1 antibody to
inhibit or reduce binding of PD-L1 to PD-1, such that
signaling/functioning through PD-1 is abolished or diminished.
[0029] As used herein, "FGFR variant" refers to an alteration in
the wild type FGFR gene, including, but not limited to, FGFR fusion
genes, FGFR mutations, FGFR amplifications, or any combination
thereof. The terms "variant" and "alteration" are used
interchangeably herein. "FGFR fusion" or "FGFR fusion gene" refers
to a gene encoding a portion of FGFR (e.g., FGRF2 or FGFR3) and one
of the herein disclosed fusion partners created by a translocation
between the two genes.
[0030] As used herein, "patient" is intended to mean any animal, in
particular, mammals. Thus, the methods are applicable to human and
nonhuman animals, although most preferably with humans. "Patient"
and "subject" may be used interchangeably herein.
[0031] "Pharmaceutically effective amount" refers to an amount of
an antibody that blocks the interaction between PD-1 and PD-L1 and
an amount of an FGFR inhibitor that treats the patient.
[0032] As used herein, "pharmaceutically acceptable salt" embraces
salts with inorganic and organic acids, such as hydrochloric acid,
nitric acid, sulfuric acid, phosphoric acid, and the like. Examples
of pharmaceutically acceptable salts are discussed in Berge, et al.
(1977) "Pharmaceuticall Acceptable Salts," J. Pharm. Sci., Vol. 66,
pp. 1-19.
[0033] As used herein, "treating" and like terms refer to reducing
the severity and/or frequency of cancer symptoms, eliminating
cancer symptoms and/or the underlying cause of said symptoms,
reducing the frequency or likelihood of cancer symptoms and/or
their underlying cause, and improving or remediating damage caused,
directly or indirectly, by cancer.
[0034] Disclosed herein are methods of treating cancer in a patient
comprising: administering to the patient a pharmaceutically
effective amount of an antibody that blocks the interaction between
PD-1 and PD-L1 and a pharmaceutically effective amount of an FGFR
inhibitor, wherein the antibody that blocks the interaction between
PD-1 and PD-L1 and the FGFR inhibitor are administered if one or
more FGFR variants are present in a biological sample from the
patient.
[0035] PD-1 is a cell surface receptor expressed on the surface of
CD4+ and CD8+ T cells, B cells, and myeloid cells. The ligands of
PD-1, PD-L1 and PD-L2, are expressed on immune cells; in addition,
PD-L1 is also expressed on cancer cells. When engaged by its
ligands, PD-1 downregulates the immune response by reducing T cell
proliferation, cytokine production and effector function.
Antibodies against PD-1 (anti-PD-1 antibodies) and/or its ligands
(anti-PD-L1 antibodies, for example) can block the interaction
between PD-1 and PD-L1, thereby inhibiting the downregulation of
the immune response. The disclosed methods comprise administering
to the patient a pharmaceutically effective amount of an antibody
that blocks the interaction between PD-1 and PD-L1. In some
embodiments, the methods can comprise administering to the patient
a pharmaceutically effective amount of an anti-PD-1 antibody. In
some embodiments, the methods can comprise administering to the
patient a pharmaceutically effective amount of an anti-PD-L1
antibody. In some embodiments, the methods can comprise
administering to the patient a pharmaceutically effective amount of
an anti-PD-1 antibody and an anti-PD-L1 antibody.
[0036] Exemplary anti-PD-1 antibodies include, but are not limited
to, OPDIVO.RTM. (nivolumab) (Bristol-Myers Squibb) and
KEYTRUDA.RTM. (pembrolizumab) (Merck). Exemplary anti-PD-L1
antibodies include, but are not limited to, MPDL3208A (Roche) and
MEDI4736 (AstraZeneca).
[0037] Exemplary FGFR inhibitors are described in U.S. Publ. No.
2013/0072457 A1 (incorporated herein by reference) and include
N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl-
)quinoxalin-6-yl]ethane-1,2-diamine (referred to herein
"JNJ-42756493"), including any tautomeric or stereochemically
isomeric forms thereof, N-oxides thereof, pharmaceutically
acceptable salts thereof, or solvates thereof (suitable R groups
are also disclosed in U.S. Publ. No. 2013/0072457 A1). Thus, in
some embodiments, the FGFR inhibitor can be the compound of formula
(I):
##STR00001##
or a pharmaceutically acceptable salt thereof. In some aspects, the
pharmaceutically acceptable salt is a HCl salt.
[0038] The antibody that blocks the interaction between PD-1 and
PD-L1 and the FGFR inhibitor can be administered as a single
therapeutic agent or can be co-administered as individual agents.
When administered as individual agents, the antibody and FGFR
inhibitor can be administered contemporaneously or sequentially in
either order. In some embodiments, the antibody that blocks the
interaction between PD-1 and PD-L1 and the FGFR inhibitor can be
administered contemporaneously. In some embodiments, the antibody
that blocks the interaction between PD-1 and PD-L1 and the FGFR
inhibitor can be administered sequentially. In some aspects, for
example, the antibody that blocks the interaction between PD-1 and
PD-L1 can be administered first, followed by administration of the
FGFR inhibitor. In other aspects, the FGFR inhibitor can be
administered first, followed by administration of the antibody that
blocks the interaction between PD-1 and PD-L1. When administered
sequentially, the antibody and FGFR inhibitor can be administered
within seconds, minutes, hours, days, or weeks of each other.
[0039] The pharmaceutically effective amount of the antibody that
blocks the interaction between PD-1 and PD-L1 and of the FGFR
inhibitor will be dependent on several factors including, but not
limited to, stage and severity of the cancer, as well as other
factors relating to the health of the patient. Those skilled in the
art would know how to determine the pharmaceutically effective
amount.
[0040] The disclosed methods are suitable for treating cancer in a
patient if one or more FGFR variants are present in a biological
sample from the patient. In some embodiments, the FGFR variant can
be one or more FGFR fusion genes. In some embodiments, the FGFR
variant can be one or more FGFR mutations. In some embodiments, the
FGFR variant can be one or more FGFR amplifications. In some
embodiments, a combination of the one or more FGFR variants can be
present in the biological sample from the patient. For example, in
some embodiments, the FGFR variants can be one or more FGFR fusion
genes and one or more FGFR mutations. In some embodiments, the FGFR
variants can be one or more FGFR fusion genes and one or more FGFR
amplifications. In some embodiments, the FGFR variants can be one
or more FGFR mutations and one or more FGFR amplifications. In yet
other embodiments, the FGFR variants can be one or more FGFR fusion
genes, mutations, and amplifications.
[0041] Exemplary FGFR fusion genes are provided in Table 1 and
include, but are not limited to: FGFR2:AFF3; FGFR2:BICC1;
FGFR2:CASP7; FGFR2:CCDC6; FGFR2:OFD1; FGFR3:BAIAP2L1;
FGFR3:TACC3-Intron; FGFR3:TACC3V1; FGFR3:TACC3V3; or a combination
thereof. The sequences of the FGFR fusion genes are disclosed in
Table 7.
TABLE-US-00001 TABLE 1 Exemplary FGFR fusion genes Fusion Gene FGFR
Exon Partner Exon FGFR2 FGFR2:AFF3 19 8 FGFR2:BICC1 19 3
FGFR2:CASP7 19 4 FGFR2:CCDC6 19 2 FGFR2:OFD1 19 3 FGFR3
FGFR3:BAIAP2L1 18 2 FGFR3:TACC3 Intron 18 4 FGFR3:TACC3 v1 18 11
FCFR3:TACC3 v3 18 10
[0042] FGFR mutations include FGFR single nucleotide polymorphism
(SNP). "FGFR single nucleotide polymorphism" (SNP) refers to a
FGFR2 or FGFR3 gene in which a single nucleotide differs among
individuals. In particular, FGFR single nucleotide polymorphism"
(SNP) refers to a FGFR3 gene in which a single nucleotide differs
among individuals. The presence of one or more of the following
FGFR SNPs in a biological sample from a patient can be determined
by methods known to those of ordinary skill in the art or methods
disclosed in U.S. Provisional Patent App. No. 62/056,159, U.S.
Patent Publication No. US2016-0090633, and WO 2016/048833, FGFR3
R248C, FGFR3 S249C, FGFR3 G370C, FGFR3 Y373C, or any combination
thereof. The sequences of the FGFR SNPs are provided in Table
2.
TABLE-US-00002 TABLE 2 FGFR3 mutant Sequence FGFR3 R248C
TCGGACCGCGGCAACTACACCTGCGTCGTGGAGAACAAGTTTGGCAGCATCCGGCAGACGT
ACACGCTGGACGTGCTGGAG GCTCCCCGCACCGGCCCATCCTGCAGGCGGGGCTGCCA
GGCCAACCAGACGGCGGTGCTGGGCAGCGACGTGGAGTTCCACTGCAAGGTGTACAGTGCG
CACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGAATGGCAGCAAGGTGGGCCCGGA
CGGCACACCCTACGTTACCGTGCTCA (SEQ ID NO: 1) FGFR3 S249C
GACCGCGGCAACTACACCTGCGTCGTGGAGAACAAGTTTGGCAGCATCCGGCAGACGTACA
CGCTGGACGTGCTGGGTGAGGGCCCTGGGGCGGCGCGGGGGTGGGGGCGGCAGTGGCGGTG
GTGGTGAGGGAGGGGGTGGCCCCTGAGCGTCATCTGCCCCCACAGAGCGCT CCCGCAC
CGGCCCATCCTGCAGGCGGGGCTGCCGGCCAACCAGACGGCGGTGCTGGGCAGCGACGTGG
AGTTCCACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGA
GGTGAATGGCAGCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGCTCAAGGTGGGC
CACCGTGTGCACGT (SEQ ID NO: 2) FGFR3 G370C
GCGGGCAATTCTATTGGGTTTTCTCATCACTCTGCGTGGCTGGTGGTGCTGCCAGCCGAGG
AGGAGCTGGTGGAGGCTGACGAGGCG GCAGTGTGTATGCAGGCATCCTCAGCTACGGG
GTGGGCTTCTTCCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCCTGCGCAGCC
CCCCCAAGAAAGGCCTGGGCTCCCCCACCGTGCACAAGATCTCCCGCTTCCCG (SEQ ID NO:
3) FGFR3 Y373C*
CTAGAGGTTCTCTCCTTGCACAACGTCACCTTTGAGGACGCCGGGGAGTACACCTGCCTGG
CGGGCAATTCTATTGGGTTTTCTCATCACTCTGCGTGGCTGGTGGTGCTGCCAGCCGAGGA
GGAGCTGGTGGAGGCTGACGAGGCGGGCAGTGTGT TGCAGGCATCCTCAGCTACGGGG
TGGGCTTCTTCCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCCTGCGCAGCCC
CCCCAAGAAAGGCCTGGGCTCCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAGC (SEQ ID
NO: 4) Sequences correspond to nucleotides 920-1510 of FGFR3
(Genebank ID # NM_000142.4). Nucleotides in bold underline
represent the SNP. *Sometimes mistakenly referred to as Y375C in
the literature.
[0043] The methods can further comprise evaluating the presence of
one or more FGFR variants in the biological sample before the
administering step. Suitable methods for evaluating a biological
sample for the presence of one or more FGFR variants are disclosed
elsewhere herein.
[0044] The disclosed methods can be dependent upon PD-L1 expression
in the cancer or can be carried out irrespectively of PD-L1
expression in the cancer. In some embodiments, for example, the
methods can comprise administering to the patient a
pharmaceutically effective amount of an antibody that blocks the
interaction between PD-1 and PD-L1 and a pharmaceutically effective
amount of an FGFR inhibitor, wherein the antibody that blocks the
interaction between PD-1 and PD-L1 and the FGFR inhibitor are
administered if one or more FGFR variants are present in a
biological sample from the patient and PD-L1 expression in the
biological sample from the patient is at a specified level or
within a specified range. In some aspects, for example, the methods
can be carried out if the PD-L1 expression is high in the
biological sample. Accordingly, in some embodiments the methods can
comprise administering to the patient a pharmaceutically effective
amount of an antibody that blocks the interaction between PD-1 and
PD-L1 and a pharmaceutically effective amount of an FGFR inhibitor,
wherein the antibody that blocks the interaction between PD-1 and
PD-L1 and the FGFR inhibitor are administered if PD-L1 expression
is high and one or more FGFR variants are present in a biological
sample from the patient. Alternatively, the methods can be carried
out if the PD-L1 expression is low in the biological sample.
Accordingly, the methods can comprise administering to the patient
a pharmaceutically effective amount of an antibody that blocks the
interaction between PD-1 and PD-L1 and a pharmaceutically effective
amount of an FGFR inhibitor, wherein the antibody that blocks the
interaction between PD-1 and PD-L1 and the FGFR inhibitor are
administered if PD-L1 expression is low and one or more FGFR
variants are present in a biological sample from the patient. The
methods can be carried out if the PD-L1 expression is moderate.
Accordingly, the methods can comprise administering to the patient
a pharmaceutically effective amount of an antibody that blocks the
interaction between PD-1 and PD-L1 and a pharmaceutically effective
amount of an FGFR inhibitor, wherein the antibody that blocks the
interaction between PD-1 and PD-L1 and the FGFR inhibitor are
administered if PD-L1 expression is moderate and one or more FGFR
variants are present in a biological sample from the patient. As
discussed elsewhere herein, PD-L1 expression levels can be based
upon a numerical H-score (low includes an H-score of about 0 to
about 99; moderate includes an H-score of about 100 to about 199;
and high includes an H-score of about 200 to about 300) or can be
based upon a comparison to a reference value.
[0045] In other embodiments, the methods can be carried out
irrespectively of PD-L1 expression in the biological sample from
the patient and can be based on the presence of one or more FGFR
variants without factoring in PD-L1 expression.
[0046] The methods can further comprise evaluating PD-L1 expression
in the biological sample from the patient. Exemplary methods of
evaluating PD-L1 expression are disclosed elsewhere herein. PD-L1
expression can be evaluated before, during, or after the
administering step.
[0047] In some embodiments, the methods can comprise evaluating the
presence of one or more FGFR variants and PD-L1 expression in the
biological sample from the patient before the administering
step.
[0048] Suitable biological samples for evaluating PD-L1 expression,
evaluating the presence of one or more FGFR variants, or for
evaluating both PD-L1 expression and the presence of one or more
FGFR variants include, but are not limited to, blood, lymph fluid,
bone marrow, a solid tumor sample, or any combination thereof.
[0049] The disclosed methods can be used to treat a variety of
cancer types including, but not limited to, lung cancer, bladder
cancer, gastric cancer, breast cancer, ovarian cancer, head and
neck cancer, esophageal cancer, glioblastoma, or any combination
thereof. In some embodiments, the methods can be used to treat lung
cancer. The lung cancer can be non-small cell lung cancer (NSCLC)
adenocarcinoma, NSCLC squamous cell carcinoma, small cell lung
cancer, or any combination thereof. Thus, in some aspects, the
methods can be used to treat NSCLC adenocarcinoma. In other
aspects, the methods can be used to treat NSCLC squamous cell
carcinoma. In yet other aspects, the methods can be used to treat
small cell lung cancer. In some embodiments, the methods can be
used to treat bladder cancer. In some embodiments, the methods can
be used to treat gastric cancer. In some embodiments, the methods
can be used to treat breast cancer. In some embodiments, the
methods can be used to treat ovarian cancer. In some embodiments,
the methods can be used to treat head and neck cancer. In some
embodiments, the methods can be used to treat esophageal cancer. In
some embodiments, the methods can be used to treat glioblastoma. In
some embodiments, the methods can be used to treat any combination
of the above cancers.
[0050] Also disclosed are methods of treating cancer in a patient
comprising: administering to the patient a pharmaceutically
effective amount of an antibody that blocks the interaction between
PD-1 and PD-L1; monitoring the efficacy of the antibody; and if the
antibody is not efficacious, evaluating a biological sample from
the patient for a presence of one or more FGFR variants and
administering to the patient a pharmaceutically effective amount of
an FGFR inhibitor if the one or more FGFR variants are present in
the sample.
[0051] The efficacy of the antibody can be monitored by, for
example, evaluating the patient's symptoms for progression of the
cancer, evaluating the severity of the cancer symptoms, evaluating
the frequency of the cancer symptoms, measuring tumor size, or any
combination thereof. Without intent to be limiting, progression or
failure to reduce the progression of the cancer, increased severity
or no change in severity of the cancer symptoms, increased
frequency or no change in the frequency of the cancer symptoms,
increased size or no change in size of the tumor, or any
combination thereof, can be indications that the antibody is not
efficacious.
[0052] In some embodiments, the methods can comprise administering
to the patient a pharmaceutically effective amount of an anti-PD-1
antibody. In some embodiments, the methods can comprise
administering to the patient a pharmaceutically effective amount of
an anti-PD-L1 antibody. In some embodiments, the methods can
comprise administering to the patient a pharmaceutically effective
amount of an anti-PD-1 antibody and an anti-PD-L1 antibody.
Exemplary anti-PD-1 antibodies include, but are not limited to,
OPDIVO.RTM. (nivolumab) (Bristol-Myers Squibb) and KEYTRUDA.RTM.
(pembrolizumab) (Merck). Exemplary anti-PD-L1 antibodies include,
but are not limited to, MPDL3208A (Roche) and MEDI4736
(AstraZeneca).
[0053] Exemplary FGFR inhibitors include those disclosed above,
including
N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl-
)quinoxalin-6-yl]ethane-1,2-diamine (referred to herein
"JNJ-42756493"), including any tautomeric or stereochemically
isomeric forms thereof, N-oxides thereof, pharmaceutically
acceptable salts thereof, or solvates thereof (suitable R groups
are also disclosed in U.S. Publ. No. 2013/0072457 A1). In some
embodiments, the FGFR inhibitor can be the compound of formula
(I):
##STR00002##
or a pharmaceutically acceptable salt thereof. In some aspects, the
pharmaceutically acceptable salt is a HCl salt.
[0054] The pharmaceutically effective amount of the antibody and
FGFR inhibitor will be dependent on several factors including, but
not limited to, stage and severity of the cancer, as well as other
factors relating to the health of the patient. Those skilled in the
art would know how to determine the pharmaceutically effective
amount.
[0055] The disclosed methods are suitable for treating cancer in a
patient if one or more FGFR variants are present in a biological
sample from the patient. In some embodiments, the FGFR variant can
be one or more FGFR fusion genes. In some embodiments, the FGFR
variant can be one or more FGFR mutations. In some embodiments, the
FGFR variant can be one or more FGFR amplifications. In some
embodiments, a combination of the one or more FGFR variants can be
present in the biological sample from the patient. For example, in
some embodiments, the FGFR variants can be one or more FGFR fusion
genes and one or more FGFR mutations. In some embodiments, the FGFR
variants can be one or more FGFR fusion genes and one or more FGFR
amplifications. In some embodiments, the FGFR variants can be one
or more FGFR mutations and one or more FGFR amplifications. In yet
other embodiments, the FGFR variants can be one or more FGFR fusion
genes, mutations, and amplifications. Exemplary FGFR fusion genes
are provided in Table 1 and include, but are not limited to:
FGFR2:AFF3; FGFR2:BICC1; FGFR2:CASP7; FGFR2:CCDC6; FGFR2:OFD1;
FGFR3:BAIAP2L1; FGFR3:TACC3-Intron; FGFR3:TACC3V1; FGFR3:TACC3V3;
or a combination thereof.
[0056] Suitable methods for evaluating a biological sample for the
presence of one or more FGFR variants are disclosed elsewhere
herein.
[0057] The disclosed methods can be dependent upon PD-L1 expression
in the biological sample or can be carried out irrespectively of
PD-L1 expression in the cancer. In some aspects, for example, if
the antibody is not efficacious, the methods can comprise measuring
an expression level of PD-L1 in the biological sample and
administering to the patient a pharmaceutically effective amount of
an FGFR inhibitor if the PD-L1 expression is at a specified level
or within a specified range. Methods of evaluating PD-L1 expression
are disclosed elsewhere herein. The methods can be carried out if
the PD-1 expression in the biological sample is low. In some
embodiments, for example, the evaluating step can further comprise
measuring an expression level of PD-L1 in the biological sample and
the second administering step can comprise administering the FGFR
inhibitor if the expression level of PD-L1 is low. In some aspects,
methods of treating cancer in a patient comprise: administering to
the patient a pharmaceutically effective amount of an antibody that
blocks the interaction between PD-1 and PD-L1; monitoring the
efficacy of the antibody; and if the antibody is not efficacious,
evaluating a biological sample from the patient for a presence of
one or more FGFR variants and measuring an expression level of
PD-L1 in the biological sample, and administering to the patient a
pharmaceutically effective amount of an FGFR inhibitor if the one
or more FGFR variants are present and if the expression level of
PD-L1 is low in the sample.
[0058] The methods can be carried out if the PD-1 expression in the
biological sample is moderate. Thus, the evaluating step can
further comprise measuring an expression level of PD-L1 in the
biological sample and the second administering step can comprise
administering the FGFR inhibitor if the expression level of PD-L1
is moderate. The methods can be carried out if the PD-1 expression
in the biological sample is high. For example, the evaluating step
can further comprise measuring an expression level of PD-L1 in the
biological sample and the second administering step can comprise
administering the FGFR inhibitor if the expression level of PD-L1
is high.
[0059] As discussed elsewhere herein, PD-L1 expression levels can
be based upon a numerical H-score (low includes an H-score of about
0 to about 99; moderate includes an H-score of about 100 to about
199; and high includes an H-score of about 200 to about 300) or can
be based upon a comparison to a reference value.
[0060] In other embodiments, the methods can be carried out
irrespectively of PD-L1 expression in the cancer and can be based
on the presence of one or more FGFR variants in the biological
sample without factoring in PD-L1 expression.
[0061] Suitable biological samples include, but are not limited to,
blood, lymph fluid, bone marrow, a solid tumor sample, or any
combination thereof.
[0062] The disclosed methods can be used to treat a variety of
cancer types including, but not limited to, lung cancer, bladder
cancer, gastric cancer, breast cancer, ovarian cancer, head and
neck cancer, esophageal cancer, glioblastoma, or any combination
thereof. In some embodiments, the methods can be used to treat lung
cancer. The lung cancer can be non-small cell lung cancer (NSCLC)
adenocarcinoma, NSCLC squamous cell carcinoma, small cell lung
cancer, or any combination thereof. Thus, in some aspects, the
methods can be used to treat NSCLC adenocarcinoma. In other
aspects, the methods can be used to treat NSCLC squamous cell
carcinoma. In yet other aspects, the methods can be used to treat
small cell lung cancer. In some embodiments, the methods can be
used to treat bladder cancer. In some embodiments, the methods can
be used to treat gastric cancer. In some embodiments, the methods
can be used to treat breast cancer. In some embodiments, the
methods can be used to treat ovarian cancer. In some embodiments,
the methods can be used to treat head and neck cancer. In some
embodiments, the methods can be used to treat esophageal cancer. In
some embodiments, the methods can be used to treat glioblastoma. In
some embodiments, the methods can be used to treat any combination
of the above cancers.
[0063] Also, disclosed herein are uses of an antibody that blocks
the interaction between PD-1 and PD-L1 and an FGFR inhibitor for
the manufacture of a medicament for the treatment of cancer, in
particular for the treatment of cancer in a patient wherein one or
more FGFR variants are present in a biological sample from the
patient. Each of the above embodiments described in terms of a
method of treating cancer can be employed in the use of an antibody
that blocks the interaction between PD-1 and PD-L1 and an FGFR
inhibitor for the manufacture of a medicament for the treatment of
cancer, in particular for the treatment of cancer in a patient
wherein one or more FGFR variants are present in a biological
sample from the patient.
[0064] Also disclosed herein are combinations of an antibody that
blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor
for use in the treatment of cancer, in particular for the treatment
of cancer in a patient wherein one or more FGFR variants are
present in a biological sample from the patient. Each of the above
embodiments described in terms of a method of treating cancer can
be employed with a combination of an antibody that blocks the
interaction between PD-1 and PD-L1 and an FGFR inhibitor for use in
the treatment of cancer, in particular for the treatment of cancer
in a patient wherein one or more FGFR variants are present in a
biological sample from the patient.
Evaluating a Sample for the Presence of One or More FGFR
Variants
[0065] The following methods for evaluating a biological sample for
the presence of one or more FGFR variants apply equally to any of
the above disclosed methods of treatment.
[0066] Suitable methods for evaluating a biological sample for the
presence of one or more FGFR variants are described in the methods
section herein and in U.S. Provisional Patent App. No. 62/056,159,
U.S. Patent Publication No. US2016-0090633, and WO 2016/048833,
which are incorporated herein in their entirety. For example, and
without intent to be limiting, evaluating a biological sample for
the presence of one or more FGFR variants can comprise any
combination of the following steps: isolating RNA from the
biological sample; synthesizing cDNA from the RNA; and amplifying
the cDNA (preamplified or non-preamplified). In some embodiments,
evaluating a biological sample for the presence of one or more FGFR
variants can comprise: amplifying cDNA from the patient with a pair
of primers that bind to and amplify one or more FGFR variants; and
determining whether the one or more FGFR variants are present in
the sample. In some aspects, the cDNA can be pre-amplified. In some
aspects, the evaluating step can comprise isolating RNA from the
sample, synthesizing cDNA from the isolated RNA, and pre-amplifying
the cDNA.
[0067] Suitable primer pairs for performing an amplification step
include, but are not limited to, those disclosed in U.S.
Provisional Patent App. No. 62/056,159, U.S. Patent Publication No.
US2016-0090633, and WO 2016/048833, as exemplified below:
TABLE-US-00003 FGFR3TACC3 V1 (SEQ ID NO: 1) Forward:
GACCTGGACCGTGTCCTTACC (SEQ ID NO: 2) Reverse: CTTCCCCAGTTCCAGGTTCTT
FGFR3TACC3 V3 (SEQ ID NO: 3) Forward: AGGACCTGGACCGTGTCCTT (SEQ ID
NO: 4) Reverse: TATAGGTCCGGTGGACAGGG FGFR3TACC3 Intron (SEQ ID NO:
5) Forward: GGCCATCCTGCCCCC (SEQ ID NO: 6) Reverse:
GAGCAGTCCAGGTCAGCCAG FGFR3BAIAP2L1 (SEQ ID NO: 7) Forward:
CTGGACCGTGTCCTTACCGT (SEQ ID NO: 8) Reverse: GCAGCCCAGGATTGAACTGT
FGFR2BICC1 (SEQ ID NO: 9) Forward: TGGATCGAATTCTCACTCTCACA (SEQ ID
NO: 10) Reverse: GCCAAGCAATCTGCGTATTTG FGFR2AFF3 (SEQ ID NO: 11)
Forward: TGGTAGAAGACTTGGATCGAATTCT (SEQ ID NO: 12) Reverse:
TCTCCCGGATTATTTCTTCAACA FGFR2CASP7 (SEQ ID NO: 13) Forward:
GCTCTTCAATACAGCCCTGATCA (SEQ ID NO: 14) Reverse:
ACTTGGATCGAATTCTCACTCTCA FGFR2CCDC6 (SEQ ID NO: 15) Forward:
TGGATCGAATTCTCACTCTCACA (SEQ ID NO: 16) Reverse:
GCAAAGCCTGAATTTTCTTGAATAA FGFR2OFD1 (SEQ ID NO: 17) Forward:
AGGGTGCATCAACTCATGAATTAG (SEQ ID NO: 18) Reverse:
ACTTGGATCGAATTCTCACTCTCA
[0068] The presence of one or more FGFR variants can be evaluated
at any suitable time point including upon diagnosis, following
tumor resection, following first-line therapy, during clinical
treatment, or any combination thereof.
Evaluating PD-L1 Expression in the Cancer
[0069] The following methods for evaluating PD-L1 expression in a
biological sample apply equally to any of the above disclosed
methods of treatment.
[0070] In some embodiments, the disclosed methods can be dependent
upon PD-L1 expression in the biological sample from the patient.
Thus, administering to the patient a pharmaceutically effective
amount of an antibody that blocks the interaction between PD-1 and
PD-L1 and a pharmaceutically effective amount of an FGFR inhibitor
may be based upon PD-L1 expression and the presence of one or more
FGFR variants in the biological sample from the patient. The
methods can comprise evaluating PD-L1 expression in a biological
sample from the patient. The biological sample from which PD-L1
expression is evaluated can be the same biological sample from
which the presence of one or more FGFR variants are evaluated, or
the biological samples from which PD-L1 expression is evaluated can
be a different biological sample from which the presence of one or
more FGFR variants are evaluated. "Same biological sample" refers
to a single sample from which both PD-L1 expression and FGFR
variants are evaluated. "Different biological sample" includes the
same source of sample (blood, lymph fluid, bone marrow, a solid
tumor sample, etc.) taken at different time points or different
sources of sample. For example, a blood sample can be obtained from
the patient, evaluated for PD-L1 expression or the presence of one
or more FGFR variants, and at a later time point, another blood
sample can be obtained from the patient and evaluated for the
presence of one or more FGFR variants or PD-L1 expression.
Conversely, a blood sample can be obtained from the patient and
evaluated for PD-L1 expression and/or the presence of one or more
FGFR variants and a solid tumor sample can be obtained from the
patient and evaluated for the presence of one or more FGFR variants
and/or PD-L1 expression.
[0071] In some embodiments, the level of PD-L1 expression can be
converted into a numerical H-score (as described in the methods
section herein). The level of PD-L1 expression can be converted
into a numerical H-score of: low PD-L1 expression, which includes
an H-score of about 0 to about 99; moderate PD-L1 expression, which
includes an H-score of about 100 to about 199; or high PD-L1
expression, which includes an H-score of about 200 to about 300.
Treating the patient can be based upon these H-scores. For example,
if the treatment methods are carried out on a patient with a low
H-score, that patient would have PD-L1 expression corresponding to
an H-score of about 0 to about 99. If the treatment methods are
carried out on a patient with a moderate H-score, that patient
would have PD-L1 expression corresponding to an H-score of about
100 to about 199. If the treatment methods are carried out on a
patient with a high H-score, that patient would have PD-L1
expression corresponding to an H-score of about 200 to about
300.
[0072] In other embodiments, the level of PD-L1 expression can be
compared to a reference PD-L1 expression level. In a preferred
embodiment, the reference PD-L1 expression level can be
predetermined. For example, a reference data set may be established
using samples from unrelated patients with low, moderate and high
PD-L1 expression levels. This data set can represent a standard by
which relative PD-L1 expression levels are compared among patients
and/or quantified using the H-Score method. In some embodiments,
the reference PD-L1 expression level can be determined by comparing
a patient population that is administered the antibody that blocks
the interaction between PD-1 and PD-L1 to a patient population that
is administered placebo. The PD-L1 expression level for each
patient in the respective populations can be determined in
accordance with the methods described herein. Clinical outcomes
(e.g., progression-free survival or overall survival) for the
patient populations can be monitored. Clinical outcomes for the
patient populations relative to PD-L1 expression levels can then be
compared. The reference PD-L1 expression level can correspond to
the PD-L1 expression level above which the patient population that
is administered the antibody that blocks the interaction between
PD-1 and PD-L1 demonstrates a statistically significant improvement
in at least one clinical outcome relative to the patient population
that is administered placebo. A patient PD-L1 expression level that
is less than the reference PD-L1 expression level, particularly
when combined with the presence of one or more FGFR variants in a
patient sample, can be indicative that the patient will benefit
from treatment with the antibody that blocks the interaction
between PD-1 and PD-L1 in combination with an FGFR inhibitor. For
example, in some embodiments, the methods can comprise
administering an antibody that blocks the interaction between PD-1
and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks
the interaction between PD-1 and PD-L1 and the FGFR inhibitor are
administered if one or more FGFR variants are present in a
biological sample from the patient and the PD-L1 expression in the
biological sample is less than a reference PD-L1 expression level,
wherein the reference PD-L1 expression level corresponds to a PD-L1
expression level above which treatment with the antibody that
blocks the interaction between PD-1 and PD-L1 alone is likely to be
efficacious.
[0073] Methods for determining PD-L1 expression include, but are
not limited to, immunohistochemistry (IHC), Western Blotting,
microscopy, immunoprecipitation, BCA assays, spectrophotometry, or
any combination thereof. Exemplary methods for evaluating PD-L1
expression are described in the methods section herein.
[0074] PD-L1 expression can be evaluated at any suitable time point
including upon diagnosis, following tumor resection, following
first-line therapy, during clinical treatment, or any combination
thereof.
[0075] The following examples are provided to further describe some
of the embodiments disclosed herein. The examples are intended to
illustrate, not to limit, the disclosed embodiments.
EXAMPLES
Methods
PD-L1 Immunohistochemistry
[0076] PD-L1 immunohistochemistry (IHC) was performed at a CRO
(QualTek, Newtown, Pa.). Samples were stained using a CD274 PD-L1
(RUO) assay. Slides stained with a CD274 PD-L1 (RUO) assay were
examined in random order and/or in blinded fashion by a
board-certified clinical pathologist, the Medical Director of
QualTek Clinical Laboratories (CAP/CLIA facility). The entire
tissue section was evaluated for CD274 PD-L1. Only viable tissue
was evaluated; areas of necrosis or obviously poorly fixed areas of
tissue were not evaluated.
[0077] The tumor H-Score was calculated from the intensity of CD274
PD-L1 membrane reactivity on a four-point semi-quantitative scale
(0: null, negative or non-specific staining of cell membranes; 1+:
low or weak intensity staining of cell membranes; 2+: medium or
moderate intensity staining of cell membranes; and 3+: high or
strong intensity staining of cell membranes) and the estimated
percentage of CD274 PD-L1 positive tumor cells (0-100%) for each
discrete intensity value.
[0078] Tumor CD274 PD-L1 membrane reactivity was captured by a
standard H-Score--the tumor H-Score minimum of 0 and the tumor
H-Score maximum of 300: Tumor H-Score=([% positive cells at
1+]*1)+([% positive cells at 2+]*2)+([% positive cells at
3+]*3)
Next-Generation Sequencing (NGS)
[0079] NGS for FGFR mutations and gene amplification was performed
by Foundation Medicine, Cambridge, Mass. using the FoundationOne
panel (http://www.foundationmedicine.com).
FGFR Fusions
[0080] FGFR fusions were determined using a proprietary qRT-PCR
assay developed by Janssen Oncology Translational Research as
described in U.S. Provisional Application No. 62/056,159, U.S.
Patent Publication No. US2016-0090633, and WO 2016/048833.
Results
[0081] PD-L1 Expression in Tumors with FGFR Fusions and
Mutations
[0082] To determine the overlap of PD-L1 expression with FGFR
alterations, immunohistochemistry (IHC) for PD-L1 was performed on
human tumor tissue samples which were subsequently assessed for
FGFR alterations. FGFR amplifications and mutations were identified
using next-generation sequencing (Foundation Medicine panel, FMI).
FGFR fusions were screened for using a Janssen-developed qRT-PCR
assay.
Correlation of FGFR Mutations and Amplification with PD-L1
[0083] PD-L1 expression was first assessed in a set of 120
commercially sourced lung FFPE tumor tissues comprised of forty of
each of the following lung tumor histologies; non-small-cell lung
carcinoma (NSCLC) adenocarcinoma; NSCLC squamous cell carcinoma;
and small-cell lung cancer (SCLC). FGFR mutations and gene
amplification were detected using the Foundation Medicine panel.
PD-L1 staining versus FGFR status was plotted for each tumor type
(FIG. 1). PD-L1 expression was largely reserved to tumors without
FGFR mutations or amplifications. Out of nine samples with FGFR
mutations, no PD-L1 staining was observed in seven samples (78%).
Two of the nine samples showed very low PD-L1 staining with
H-scores of 20 and 70, respectively. Of four samples with FGFR gene
amplification, one sample showed moderate-high PD-L1 staining
(H-score=140), with three having almost no staining (H-score=4,
n=1). No staining was observed in the one tumor sample harboring
both an FGFR mutation and FGFR gene amplification. FGFR mutation
and amplification status was unknown for 24 tumor samples, of which
nine exhibited PD-L1 staining with H-scores ranging from 55 to
220.
FGFR Fusions and PD-L1 Expression in Bladder and NSCLC
[0084] The set of 120 lung FFPE tumor tissues was subsequently
screened for FGFR fusions using a Janssen-developed qRT-PCR assay
(as described in U.S. Provisional Application No. 62/056,159, U.S.
Patent Publication No. US2016-0090633, and WO 2016/048833)
detecting nine fusions (Table 1). Results for PD-L1 expression by
FGFR fusion status for the NSCLC tumor samples (n=80) are shown in
FIG. 2. Twenty-three percent (7/31) of NSCLC adenocarcinoma
samples, and 52% (13/25) of NSCLC squamous cell carcinoma tumor
samples were positive for FGFR fusions. All fusion-positive
adenocarcinoma samples exhibited no or low PD-L1 expression, 6/7
(86%) or 1/7 (14%), respectively (Table 3). Fusion-negative
adenocarcinoma samples showed a range of PD-L1 from no expression
(12/31, 39%), low (12/31, 39%), moderate (4/31, 13%), to high PD-L1
(3/31, 10%) (Table 3). Fusion-positive squamous cell carcinoma
sample PD-L1 H-scores were equally distributed across the no
expression, low, moderate, or high expression categories (4/31, 31%
each respectively) (Table 4). Fusion-negative squamous samples also
showed a range of H-scores from no expression (6/25, 24%), low
(11/25, 44%), moderate (5/25, 20%), and high expression (3/25, 12%)
(Table 4).
TABLE-US-00004 TABLE 3 NSCLC Adenocarcinoma-PD-L1 H-Scores by FGFR
fusion status NSCLC H-Score Range Adenocarcinoma 0 1-25 26-50 51-99
100-199 200-300 Category: No Low Mod. High Fusion 6 -- -- 1 -- --
Positive (86%) (14%) Fusion 12 9 2 1 4 3 Negative (39%) (29%) (6%)
(3%) (13%) (10%)
TABLE-US-00005 TABLE 4 NSCLC Squamous Cell Carcinoma-PD-L1 H-Scores
by FGFR fusion status NSCLC H-Score Range Squamous 0 1-25 26-50
51-99 100-199 200-300 Category: No Low Mod. High Fusion 4 2 1 1 4 1
Positive (31%) (15%) (8%) (8%) (31%) (8%) Fusion 6 8 2 1 5 3
Negative (24%) (32%) (8%) (4%) (20%) (12%)
[0085] Forty-five commercially sourced bladder tumors were
sequenced for mutations by the Foundation Medicine panel (FMI),
stained for PD-L1 expression, and screened for FGFR gene fusions
using the Janssen qRT-PCR assay. Forty-two of 45 samples (93%) were
positive for FGFR fusions. Five samples (11%) were positive for an
FGFR mutation (FGFR3-R248C or FGFR3-S249C), all of which were also
positive for FGFR fusions. PD-L1 staining H-scores for samples with
FGFR alterations are summarized in Table 5, and listed in Table 6.
For FGFR fusion positive samples, 22/37 (59%) were negative for
PD-L1 staining. Ten FGFR fusion-positive samples (27%) expressed
low levels of PD-L1, and five samples (14%) showed high PD-L1
expression. All samples with both FGFR mutations and FGFR fusions
in the same tumor sample (n=5) were negative for PD-L1 staining.
Overall, PD-L1 staining was absent in 64% (27/42) of bladder
samples with FGFR alterations, keeping in mind that almost all of
the tumors in this sample set were positive for FGFR fusions.
[0086] FGFR mutation and PD-L1 expression data were available for
seven commercially sourced metastatic NSCLC samples with FGFR
fusions (Janssen). No PD-L1 staining was observed in 4/7 (57%) of
samples. Two samples exhibited very low PD-L1 staining, H-scores of
4 and 15. One sample showed moderate PD-L1 with an H-score of 160.
Interestingly, the FGFR fusion-positive sample with moderate PD-L1
staining harbored an FGFR4 V550I mutation--an FGFR gatekeeper
residue mutation with potential to confer resistance to tyrosine
kinase inhibitors.
[0087] Overall these data show that the majority of commercially
available tumor samples harboring FGFR alterations have very little
expression or do not express PD-L1.
TABLE-US-00006 TABLE 5 PD-L1 staining in FGFR fusion positive
bladder samples H-Score Range n = 42 0 1-25 26-50 51-99 100-199
200-300 Category: No Low Mod. High Fusion Positive 22 8 -- 2 -- 5
Fusion + 5 -- -- -- -- -- Mutation %, of Total 64% 19% 0% 5% 0% 12%
FGFR+ Samples Expressing per Category
TABLE-US-00007 TABLE 6 PD-L1 expression, FGFR fusion and mutation
status in commercial bladder and NSCLC tumor samples Janssen Tumor
FGFR H-Score Sample ID Type FGFR Fusion Gene(s) Mutation (0-300)
2329 Bladder None None 300 2425 Bladder FGFR3:BAIA/FGFR2:CASP7/
None 300 FGFR2:OFD1 F26993.C3a Bladder FGFR3:BAIA/FGFR2:AFF/ None
300 FGFR2:CASP7/FGFR2:CCDC6 F5244.E22b Bladder FGFR2:CASP7 None 300
F28052.E14a Bladder FGFR2:BICC1/FGFR2:AFF3/ None 280 FGFR2:CCDC6
F27999.D25 Bladder FGFR3:BAIA/FGFR2:CCDC6 None 250 F7799.H25b
Bladder FGFR3:BAIAP2L/FGFR2:CASP7/ None 70 FGFR2:OFD F28057.D1a
Bladder FGFR3:BAIA None 60 F15377.A2 Bladder FGFR2:AFF3 None 21
F28137.G3b Bladder FGFR3:TACC3v3/FGFR2:AFF3 None 20 F7538.A1b
Bladder FGFR3:BAIAP2L/FGFR2:BICC1/ None 20 FGFR:AFF3/FGFR2:CASP7
F26375.A2 Bladder FGFR3:BAIA/FGFR2:AFF/ None 18 FGFR2:CASP7
F7830.G3ba Bladder FGFR2:CASP7 None 10 F7860.B2b Bladder
FGFR2:AFF3FGFR2:CASP7 None 10 F27338.C4a Bladder
FGFR3:BAIA/FGFR2:CASP7 None 6 F5242.G10ba Bladder FGFR2:CASP7 None
3 2319 Bladder FGFR2:CASP7 None 0 2321 Bladder None None 0 2346
Bladder FGFR3:BAIA/FGFR2:CASP7/ None 0 FGFR2:OFD1 2347 Bladder
FGFR3:BAIAP2L1/ FGFR3-S249C 0 FGFR2:CCDC6 2362 Bladder
FGFR3:TACC3v1/FGFR3:TACC3v3/ FGFR3-S249C 0
FGFR3:BAIA/FGFR2:BICC1/FGFR2: AFF3/FGFR2:CASP7/FGFR2: CCDC6 2376
Bladder FGFR3:TACC3,v1/FGFR2: None 0 BICC1/FGFR2:CASP7 2381 Bladder
FGFR3:BAIA/FGFR2:AFF3/ FGFR3-R248C 0 FGFR2:CASP7 FGFR3-S249C 2430
Bladder FGFR3:BAIA/FGFR2:CASP7 None 0 2434 Bladder FGFR3:BAIA None
0 2458 Bladder FGFR3:BAIA/FGFR2:AFF3/ FGFR3-R248C 0 FGFR2:CASP7
2455 Bladder None None 0 2473 Bladder FGFR2:AFF3/FGFR2:OFD1 None 0
2480 Bladder FGFR2:OFD1 None 0 2518 Bladder FGFR3:BAIA/FGFR2:AFF3/
None 0 FGFR2:CASP7/FGFGFR2:OFD1 2533 Bladder FGFR2:OFD1 None 0 2541
Bladder FGFR2:CASP7/FGFR2:OFD1 None 0 2561 Bladder
FGFR3:BAIA/FGFR2:BICC1/ None 0 FGFR2:AFF3/FGFR2:CASP7 2563 Bladder
FGFR2:OFD1 None 0 4916 Bladder FGFR2:OFD1 None 0 F27064.CFS Bladder
FGFR3:BAIA/FGFR2:AFF/ None 0 FGFR2:CASP7 F28132.Ba Bladder
FGFR3:TACC3v1/FGFR3:BAIAP2L/ None 0 FGFR2:BICC1/FGFR2:CCDC6
F7269.C2 Bladder FGFR3:BAIAP2L/FGFR2:CASP7 None 0 F7271.AFSb
Bladder FGFR2:AFF3/FGFR2:CASP7 None 0 F7467.D1bb Bladder
FGFR2:AFF3/FGFR2:CASP7/ None 0 FGFR2:CCDC6 F7484.BFSc Bladder
FGFR2:AFF3 None 0 F7502.D1b Bladder FGFR2:AFF3/FGFR2:CASP7
FGFR3-S249C 0 F7789.DFSb Bladder FGFR3:BAIAP2L/FGFR2:CASP7
FGFR2-M537I 0 F7876.D1bb Bladder FGFR3:BAIAP2L/FGFR2:OFD1 None 0
I-7290.E13a Bladder FGFR2:CASP7 None 0 CNT06GK NSCLC
FGFR3:TACC3intron FGFR4-V550I 160 CNT0RHX NSCLC FGFR3:BAIAP2L None
15 CNT0RFD NSCLC FGFR2:BICC1 None 4 CNT06FI NSCLC FGFR2:AFF3 None 0
CNT06FJ NSCLC FGFR2:CCDC6 None 0 CNT06G5 NSCLC
FGFR3:TACC3v1/FGFR3:TACC3intron/ None 0 FGFR2:AFF3 CNT0RFX NSCLC
FGFR3:BAIAP2L/FGFR2:CASP7 None 0
FGFR In Vitro Experiments
[0088] To determine the effects of JNJ427564493 on immune cell
viability in vitro, peripheral blood mononuclear cells (PBMCs) from
normal donors were stimulated with anti-CD3 antibodies to activate
T cells, in the presence of increasing concentrations of
JNJ42756493. Unstimulated PBMCs were also included to determine if
JNJ42756493 affected unactivated immune populations. Cell viability
was assessed at four different time points, over 6 days. FIG. 3
shows the luminescence signal, as a measurement of cell viability,
in the presence of increasing concentrations of JNJ42756493 (up to
1 .mu.M) at days 1, 2, 5 and 6 post-treatment. For both the
stimulated and unstimulated groups, at all time points tested, cell
viability remained constant with increasing concentrations of
compound. These data suggest that the addition of JNJ42756493 does
not impair immune cell viability.
[0089] JNJ42756493 was next tested to analyze the impact on the
activity of anti-PD-1 antibodies in two in vitro functional assays:
Mixed Lymphocyte Reaction (MLR); and Cytomegalovirus antigen assay
(CMV). For the MLR assay, CD4.sup.+ T cells are stimulated with
allogeneic dendritic cells, leading to T cell activation and
IFN-.gamma. secretion. In this assay, anti-PD-1 antibodies caused
dose-dependent increases in IFN-.gamma. levels (FIG. 4, PD-1
alone). When T cells and DCs were treated with 0.01, 1 or 100 nM of
JNJ42756493, IFN-.gamma. levels were similar to those observed in
the untreated samples (FIG. 4, JNJ-493 alone vs controls),
suggesting that FGFR inhibition does not affect T cell activation.
Furthermore, combinations of JNJ42756493 with anti-PD-1 antibodies
caused similar IFN-.gamma. secretion as observed with anti-PD-1
treatment alone (FIG. 4, JNJ-493+ anti-PD-1 compared to PD-1
alone). These results suggest that JNJ42756493 does not impair the
functional activity of anti-PD-1 antibodies in the MLR assay.
[0090] In the CMV assay, PBMCs from CMV-reactive donors were
stimulated by the addition of CMV antigen. CMV-reactive T cells are
active, expand and secrete pro-inflammatory cytokines such as
IFN-.gamma.. In the presence of anti-PD-1 antibodies, significantly
higher levels of IFN-.gamma. were secreted upon CMV stimulation
(FIG. 5, PD-1 alone). In contrast, JNJ42756493 alone had no impact
on cytokine levels (FIG. 5, JNJ-493 alone). Similarly, JNJ42756493
combinations with anti-PD-1 antibodies led to similar increases of
IFN-.gamma. as seen with anti-PD-1 alone (FIG. 5,
JNJ42756493+anti-PD-1 compared to PD-1 alone). These data show that
JNJ42756493 does not affect the activity of anti-PD-1 antibodies in
the CMV assay.
[0091] Those skilled in the art will appreciate that numerous
changes and modifications can be made to the preferred embodiments
and that such changes and modifications can be made without
departing from the spirit of the invention. It is, therefore,
intended that the appended claims cover all such equivalent
variations as fall within the true spirit and scope of the
invention.
[0092] The disclosures of each patent, patent application, and
publication cited or described in this document are hereby
incorporated herein by reference, in its entirety.
Nucleotide Sequence of FGFR Fusion Genes
[0093] The nucleotide sequences for the FGFR fusion cDNA are
provided in Table 7. The underlined sequences correspond to either
FGFR3 or FGFR2, the sequences in black represent the fusion
partners and the sequence in italic fonts represent the intron
sequence of the FGFR3 gene.
TABLE-US-00008 TABLE 7 FGFR3: TACC3 v1
>ATGGGCGCCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCG
(2850 base pairs)
CCTCCTCGGAGTCCTTGGGGACGGAGCAGCGCGTCGTGGGGCGAGCGGCAGAAGTCCCG (SEQ ID
NO: 19) GGCCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCGGGGATGCTGTGGAGCT
GAGCTGTCCCCCGCCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCA
CAGGGCTGGTGCCCTCGGAGCGTGTCCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAAT
GCCTCCCACGAGGACTCCGGGGCCTACAGCTGCCGGCAGCGGCTCACGCAGCGCGTACT
GTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATGACGAAGACGGGG
AGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCCTTACTGGACACGGCCCGAG
CGGATGGACAAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCC
AGCCGCTGGCAACCCCACTCCCTCCATCTCCTGGCTGAAGAACGGCAGGGAGTTCCGCG
GCGAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGGTCATGGAA
AGCGTGGTGCCCTCGGACCGCGGCAACTACACCTGCGTCGTGGAGAACAAGTTTGGCAG
CATCCGGCAGACGTACACGCTGGACGTGCTGGAGCGCTCCCCGCACCGGCCCATCCTGC
AGGCGGGGCTGCCGGCCAACCAGACGGCGGTGCTGGGCAGCGACGTGGAGTTCCACTGC
AAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGAATGG
CAGCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGCTCAAGACGGCGGGCGCTA
ACACCACCGACAAGGAGCTAGAGGTTCTCTCCTTGCACAACGTCACCTTTGAGGACGCC
GGGGAGTACACCTGCCTGGCGGGCAATTCTATTGGGTTTTCTCATCACTCTGCGTGGCT
GGTGGTGCTGCCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTGTGTATG
CAGGCATCCTCAGCTACGGGGTGGGCTTCTTCCTGTTCATCCTGGTGGTGGCGGCTGTG
ACGCTCTGCCGCCTGCGCAGCCCCCCCAAGAAAGGCCTGGGCTCCCCCACCGTGCACAA
GATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCTGGAGTCCAACGCGTCCATGAGCT
CCAACACACCACTGGTGCGCATCGCAAGGCTGTCCTCAGGGGAGGGCCCCACGCTGGCC
AATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAAATGGGAGCTGTCTCGGGCCCGGCT
GACCCTGGGCAAGCCCCTTGGGGAGGGCTGCTTCGGCCAGGTGGTCATGGCGGAGGCCA
TCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTCACCGTAGCCGTGAAGATGCTGAAA
GACGATGCCACTGACAAGGACCTGTCGGACCTGGTGTCTGAGATGGAGATGATGAAGAT
GATCGGGAAACACAAAAACATCATCAACCTGCTGGGCGCCTGCACGCAGGGCGGGCCCC
TGTACGTGCTGGTGGAGTACGCGGCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGG
CGGCCCCCGGGCCTGGACTACTCCTTCGACACCTGCAAGCCGCCCGAGGAGCAGCTCAC
CTTCAAGGACCTGGTGTCCTGTGCCTACCAGGTGGCCCGGGGCATGGAGTACTTGGCCT
CCCAGAAGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAAC
GTGATGAAGATCGCAGACTTCGGGCTGGCCCGGGACGTGCACAACCTCGACTACTACAA
GAAGACGACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGCCTTGTTTGACC
GAGTCTACACTCACCAGAGTGACGTCTGGTCCTTTGGGGTCCTGCTCTGGGAGATCTTC
ACGCTGGGGGGCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAA
GGAGGGCCACCGCATGGACAAGCCCGCCAACTGCACACACGACCTGTACATGATCATGC
GGGAGTGCTGGCATGCCGCGCCCTCCCAGAGGCCCACCTTCAAGCAGCTGGTGGAGGAC
CTGGACCGTGTCCTTACCGTGACGTCCACCGACGTAAAGGCGACACAGGAGGAGAACCG
GGAGCTGAGGAGCAGGTGTGAGGAGCTCCACGGGAAGAACCTGGAACTGGGGAAGATCA
TGGACAGGTTCGAAGAGGTTGTGTACCAGGCCATGGAGGAAGTTCAGAAGCAGAAGGAA
CTTTCCAAAGCTGAAATCCAGAAAGTTCTAAAAGAAAAAGACCAACTTACCACAGATCT
GAACTCCATGGAGAAGTCCTTCTCCGACCTCTTCAAGCGTTTTGAGAAACAGAAAGAGG
TGATCGAGGGCTACCGCAAGAACGAAGAGTCACTGAAGAAGTGCGTGGAGGATTACCTG
GCAAGGATCACCCAGGAGGGCCAGAGGTACCAAGCCCTGAAGGCCCACGCGGAGGAGAA
GCTGCAGCTGGCAAACGAGGAGATCGCCCAGGTCCGGAGCAAGGCCCAGGCGGAAGCGT
TGGCCCTCCAGGCCAGCCTGAGGAAGGAGCAGATGCGCATCCAGTCGCTGGAGAAGACA
GTGGAGCAGAAGACTAAAGAGAACGAGGAGCTGACCAGGATCTGCGACGACCTCATCTC
CAAGATGGAGAAGATCTGA FGFR3: TACC3 v3
>ATGGGCGCCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCG
(2955 base pairs)
CCTCCTCGGAGTCCTTGGGGACGGAGCAGCGCGTCGTGGGGCGAGCGGCAGAAGTCCCG (SEQ ID
NO: 20) GGCCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCGGGGATGCTGTGGAGCT
GAGCTGTCCCCCGCCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCA
CAGGGCTGGTGCCCTCGGAGCGTGTCCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAAT
GCCTCCCACGAGGACTCCGGGGCCTACAGCTGCCGGCAGCGGCTCACGCAGCGCGTACT
GTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATGACGAAGACGGGG
AGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCCTTACTGGACACGGCCCGAG
CGGATGGACAAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCC
AGCCGCTGGCAACCCCACTCCCTCCATCTCCTGGCTGAAGAACGGCAGGGAGTTCCGCG
GCGAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGGTCATGGAA
AGCGTGGTGCCCTCGGACCGCGGCAACTACACCTGCGTCGTGGAGAACAAGTTTGGCAG
CATCCGGCAGACGTACACGCTGGACGTGCTGGAGCGCTCCCCGCACCGGCCCATCCTGC
AGGCGGGGCTGCCGGCCAACCAGACGGCGGTGCTGGGCAGCGACGTGGAGTTCCACTGC
AAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGAATGG
CAGCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGCTCAAGACGGCGGGCGCTA
ACACCACCGACAAGGAGCTAGAGGTTCTCTCCTTGCACAACGTCACCTTTGAGGACGCC
GGGGAGTACACCTGCCTGGCGGGCAATTCTATTGGGTTTTCTCATCACTCTGCGTGGCT
GGTGGTGCTGCCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTGTGTATG
CAGGCATCCTCAGCTACGGGGTGGGCTTCTTCCTGTTCATCCTGGTGGTGGCGGCTGTG
ACGCTCTGCCGCCTGCGCAGCCCCCCCAAGAAAGGCCTGGGCTCCCCCACCGTGCACAA
GATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCTGGAGTCCAACGCGTCCATGAGCT
CCAACACACCACTGGTGCGCATCGCAAGGCTGTCCTCAGGGGAGGGCCCCACGCTGGCC
AATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAAATGGGAGCTGTCTCGGGCCCGGCT
GACCCTGGGCAAGCCCCTTGGGGAGGGCTGCTTCGGCCAGGTGGTCATGGCGGAGGCCA
TCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTCACCGTAGCCGTGAAGATGCTGAAA
GACGATGCCACTGACAAGGACCTGTCGGACCTGGTGTCTGAGATGGAGATGATGAAGAT
GATCGGGAAACACAAAAACATCATCAACCTGCTGGGCGCCTGCACGCAGGGCGGGCCCC
TGTACGTGCTGGTGGAGTACGCGGCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGG
CGGCCCCCGGGCCTGGACTACTCCTTCGACACCTGCAAGCCGCCCGAGGAGCAGCTCAC
CTTCAAGGACCTGGTGTCCTGTGCCTACCAGGTGGCCCGGGGCATGGAGTACTTGGCCT
CCCAGAAGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAAC
GTGATGAAGATCGCAGACTTCGGGCTGGCCCGGGACGTGCACAACCTCGACTACTACAA
GAAGACGACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGCCTTGTTTGACC
GAGTCTACACTCACCAGAGTGACGTCTGGTCCTTTGGGGTCCTGCTCTGGGAGATCTTC
ACGCTGGGGGGCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAA
GGAGGGCCACCGCATGGACAAGCCCGCCAACTGCACACACGACCTGTACATGATCATGC
GGGAGTGCTGGCATGCCGCGCCCTCCCAGAGGCCCACCTTCAAGCAGCTGGTGGAGGAC
CTGGACCGTGTCCTTACCGTGACGTCCACCGACGTGCCAGGCCCACCCCCAGGTGTTCC
CGCGCCTGGGGGCCCACCCCTGTCCACCGGACCTATAGTGGACCTGCTCCAGTACAGCC
AGAAGGACCTGGATGCAGTGGTAAAGGCGACACAGGAGGAGAACCGGGAGCTGAGGAGC
AGGTGTGAGGAGCTCCACGGGAAGAACCTGGAACTGGGGAAGATCATGGACAGGTTCGA
AGAGGTTGTGTACCAGGCCATGGAGGAAGTTCAGAAGCAGAAGGAACTTTCCAAAGCTG
AAATCCAGAAAGTTCTAAAAGAAAAAGACCAACTTACCACAGATCTGAACTCCATGGAG
AAGTCCTTCTCCGACCTCTTCAAGCGTTTTGAGAAACAGAAAGAGGTGATCGAGGGCTA
CCGCAAGAACGAAGAGTCACTGAAGAAGTGCGTGGAGGATTACCTGGCAAGGATCACCC
AGGAGGGCCAGAGGTACCAAGCCCTGAAGGCCCACGCGGAGGAGAAGCTGCAGCTGGCA
AACGAGGAGATCGCCCAGGTCCGGAGCAAGGCCCAGGCGGAAGCGTTGGCCCTCCAGGC
CAGCCTGAGGAAGGAGCAGATGCGCATCCAGTCGCTGGAGAAGACAGTGGAGCAGAAGA
CTAAAGAGAACGAGGAGCTGACCAGGATCTGCGACGACCTCATCTCCAAGATGGAGAAG ATCTGA
FGFR3
>ATGGGCGCCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCG
Intron: TACC3
CCTCCTCGGAGTCCTTGGGGACGGAGCAGCGCGTCGTGGGGCGAGCGGCAGAAGTCCCG (4462
base pairs)
GGCCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCGGGGATGCTGTGGAGCT (SEQ ID
NO: 21) GAGCTGTCCCCCGCCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCA
CAGGGCTGGTGCCCTCGGAGCGTGTCCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAAT
GCCTCCCACGAGGACTCCGGGGCCTACAGCTGCCGGCAGCGGCTCACGCAGCGCGTACT
GTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATGACGAAGACGGGG
AGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCCTTACTGGACACGGCCCGAG
CGGATGGACAAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCC
AGCCGCTGGCAACCCCACTCCCTCCATCTCCTGGCTGAAGAACGGCAGGGAGTTCCGCG
GCGAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGGTCATGGAA
AGCGTGGTGCCCTCGGACCGCGGCAACTACACCTGCGTCGTGGAGAACAAGTTTGGCAG
CATCCGGCAGACGTACACGCTGGACGTGCTGGAGCGCTCCCCGCACCGGCCCATCCTGC
AGGCGGGGCTGCCGGCCAACCAGACGGCGGTGCTGGGCAGCGACGTGGAGTTCCACTGC
AAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGAATGG
CAGCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGCTCAAGACGGCGGGCGCTA
ACACCACCGACAAGGAGCTAGAGGTTCTCTCCTTGCACAACGTCACCTTTGAGGACGCC
GGGGAGTACACCTGCCTGGCGGGCAATTCTATTGGGTTTTCTCATCACTCTGCGTGGCT
GGTGGTGCTGCCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTGTGTATG
CAGGCATCCTCAGCTACGGGGTGGGCTTCTTCCTGTTCATCCTGGTGGTGGCGGCTGTG
ACGCTCTGCCGCCTGCGCAGCCCCCCCAAGAAAGGCCTGGGCTCCCCCACCGTGCACAA
GATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCTGGAGTCCAACGCGTCCATGAGCT
CCAACACACCACTGGTGCGCATCGCAAGGCTGTCCTCAGGGGAGGGCCCCACGCTGGCC
AATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAAATGGGAGCTGTCTCGGGCCCGGCT
GACCCTGGGCAAGCCCCTTGGGGAGGGCTGCTTCGGCCAGGTGGTCATGGCGGAGGCCA
TCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTCACCGTAGCCGTGAAGATGCTGAAA
GACGATGCCACTGACAAGGACCTGTCGGACCTGGTGTCTGAGATGGAGATGATGAAGAT
GATCGGGAAACACAAAAACATCATCAACCTGCTGGGCGCCTGCACGCAGGGCGGGCCCC
TGTACGTGCTGGTGGAGTACGCGGCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGG
CGGCCCCCGGGCCTGGACTACTCCTTCGACACCTGCAAGCCGCCCGAGGAGCAGCTCAC
CTTCAAGGACCTGGTGTCCTGTGCCTACCAGGTGGCCCGGGGCATGGAGTACTTGGCCT
CCCAGAAGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAAC
GTGATGAAGATCGCAGACTTCGGGCTGGCCCGGGACGTGCACAACCTCGACTACTACAA
GAAGACGACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGCCTTGTTTGACC
GAGTCTACACTCACCAGAGTGACGTCTGGTCCTTTGGGGTCCTGCTCTGGGAGATCTTC
ACGCTGGGGGGCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAA
GGAGGGCCACCGCATGGACAAGCCCGCCAACTGCACACACGACCTGTACATGATCATGC
GGGAGTGCTGGCATGCCGCGCCCTCCCAGAGGCCCACCTTCAAGCAGCTGGTGGAGGAC
CTGGACCGTGTCCTTACCGTGACGTCCACCGACgtgagtgctggctctggcctggtgcc
acccgcctatgcccctccccctgccgtccccggccatcctgccccccagagtgctgagg
tgtggggcgggccttTCTGGCCCAGGTGCCCTGGCTGACCTGGACTGCTCAAGCTCTTC
CCAGAGCCCAGGAAGTTCTGAGAACCAAATGGTGTCTCCAGGAAAAGTGTCTGGCAGCC
CTGAGCAAGCCGTGGAGGAAAACCTTAGTTCCTATTCCTTAGACAGAAGAGTGACACCC
GCCTCTGAGACCCTAGAAGACCCTTGCAGGACAGAGTCCCAGCACAAAGCGGAGACTCC
GCACGGAGCCGAGGAAGAATGCAAAGCGGAGACTCCGCACGGAGCCGAGGAGGAATGCC
GGCACGGTGGGGTCTGTGCTCCCGCAGCAGTGGCCACTTCGCCTCCTGGTGCAATCCCT
AAGGAAGCCTGCGGAGGAGCACCCCTGCAGGGTCTGCCTGGCGAAGCCCTGGGCTGCCC
TGCGGGTGTGGGCACCCCCGTGCCAGCAGATGGCACTCAGACCCTTACCTGTGCACACA
CCTCTGCTCCTGAGAGCACAGCCCCAACCAACCACCTGGTGGCTGGCAGGGCCATGACC
CTGAGTCCTCAGGAAGAAGTGGCTGCAGGCCAAATGGCCAGCTCCTCGAGGAGCGGACC
TGTAAAACTAGAATTTGATGTATCTGATGGCGCCACCAGCAAAAGGGCACCCCCACCAA
GGAGACTGGGAGAGAGGTCCGGCCTCAAGCCTCCCTTGAGGAAAGCAGCAGTGAGGCAG
CAAAAGGCCCCGCAGGAGGTGGAGGAGGACGACGGTAGGAGCGGAGCAGGAGAGGACCC
CCCCATGCCAGCTTCTCGGGGCTCTTACCACCTCGACTGGGACAAAATGGATGACCCAA
ACTTCATCCCGTTCGGAGGTGACACCAAGTCTGGTTGCAGTGAGGCCCAGCCCCCAGAA
AGCCCTGAGACCAGGCTGGGCCAGCCAGCGGCTGAACAGTTGCATGCTGGGCCTGCCAC
GGAGGAGCCAGGTCCCTGTCTGAGCCAGCAGCTGCATTCAGCCTCAGCGGAGGACACGC
CTGTGGTGCAGTTGGCAGCCGAGACCCCAACAGCAGAGAGCAAGGAGAGAGCCTTGAAC
TCTGCCAGCACCTCGCTTCCCACAAGCTGTCCAGGCAGTGAGCCAGTGCCCACCCATCA
GCAGGGGCAGCCTGCCTTGGAGCTGAAAGAGGAGAGCTTCAGAGACCCCGCTGAGGTTC
TAGGCACGGGCGCGGAGGTGGATTACCTGGAGCAGTTTGGAACTTCCTCGTTTAAGGAG
TCGGCCTTGAGGAAGCAGTCCTTATACCTCAAGTTCGACCCCCTCCTGAGGGACAGTCC
TGGTAGACCAGTGCCCGTGGCCACCGAGACCAGCAGCATGCACGGTGCAAATGAGACTC
CCTCAGGACGTCCGCGGGAAGCCAAGCTTGTGGAGTTCGATTTCTTGGGAGCACTGGAC
ATTCCTGTGCCAGGCCCACCCCCAGGTGTTCCCGCGCCTGGGGGCCCACCCCTGTCCAC
CGGACCTATAGTGGACCTGCTCCAGTACAGCCAGAAGGACCTGGATGCAGTGGTAAAGG
CGACACAGGAGGAGAACCGGGAGCTGAGGAGCAGGTGTGAGGAGCTCCACGGGAAGAAC
CTGGAACTGGGGAAGATCATGGACAGGTTCGAAGAGGTTGTGTACCAGGCCATGGAGGA
AGTTCAGAAGCAGAAGGAACTTTCCAAAGCTGAAATCCAGAAAGTTCTAAAAGAAAAAG
ACCAACTTACCACAGATCTGAACTCCATGGAGAAGTCCTTCTCCGACCTCTTCAAGCGT
TTTGAGAAACAGAAAGAGGTGATCGAGGGCTACCGCAAGAACGAAGAGTCACTGAAGAA
GTGCGTGGAGGATTACCTGGCAAGGATCACCCAGGAGGGCCAGAGGTACCAAGCCCTGA
AGGCCCACGCGGAGGAGAAGCTGCAGCTGGCAAACGAGGAGATCGCCCAGGTCCGGAGC
AAGGCCCAGGCGGAAGCGTTGGCCCTCCAGGCCAGCCTGAGGAAGGAGCAGATGCGCAT
CCAGTCGCTGGAGAAGACAGTGGAGCAGAAGACTAAAGAGAACGAGGAGCTGACCAGGA
TCTGCGACGACCTCATCTCCAAGATGGAGAAGATCTGA FGFR3: BAIAP2L1
>ATGGGCGCCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCG
(3765 base pairs)
CCTCCTCGGAGTCCTTGGGGACGGAGCAGCGCGTCGTGGGGCGAGCGGCAGAAGTCCCG (SEQ ID
NO: 22) GGCCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCGGGGATGCTGTGGAGCT
GAGCTGTCCCCCGCCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCA
CAGGGCTGGTGCCCTCGGAGCGTGTCCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAAT
GCCTCCCACGAGGACTCCGGGGCCTACAGCTGCCGGCAGCGGCTCACGCAGCGCGTACT
GTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATGACGAAGACGGGG
AGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCCTTACTGGACACGGCCCGAG
CGGATGGACAAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCC
AGCCGCTGGCAACCCCACTCCCTCCATCTCCTGGCTGAAGAACGGCAGGGAGTTCCGCG
GCGAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGGTCATGGAA
AGCGTGGTGCCCTCGGACCGCGGCAACTACACCTGCGTCGTGGAGAACAAGTTTGGCAG
GCAGCATCCGGCAGACGTACACGCTGGACGTGCTGGAGCGCTCCCCGCACCGGCCCATC
CTGCAGGCGGGGCTGCCGGCCAACCAGACGGCGGTGCTGGGCAGCGACGTGGAGTTCCA
CTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA
ATGGCAGCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGCTCAAGTCCTGGATC
AGTGAGAGTGTGGAGGCCGACGTGCGCCTCCGCCTGGCCAATGTGTCGGAGCGGGACGG
GGGCGAGTACCTCTGTCGAGCCACCAATTTCATAGGCGTGGCCGAGAAGGCCTTTTGGC
TGAGCGTTCACGGGCCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGC
AGTGTGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCCTGTTCATCCTGGTGGT
GGCGGCTGTGACGCTCTGCCGCCTGCGCAGCCCCCCCAAGAAAGGCCTGGGCTCCCCCA
CCGTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCTGGAGTCCAACGCG
TCCATGAGCTCCAACACACCACTGGTGCGCATCGCAAGGCTGTCCTCAGGGGAGGGCCC
CACGCTGGCCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAAATGGGAGCTGTCTC
GGGCCCGGCTGACCCTGGGCAAGCCCCTTGGGGAGGGCTGCTTCGGCCAGGTGGTCATG
GCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTCACCGTAGCCGTGAA
GATGCTGAAAGACGATGCCACTGACAAGGACCTGTCGGACCTGGTGTCTGAGATGGAGA
TGATGAAGATGATCGGGAAACACAAAAACATCATCAACCTGCTGGGCGCCTGCACGCAG
GGCGGGCCCCTGTACGTGCTGGTGGAGTACGCGGCCAAGGGTAACCTGCGGGAGTTTCT
GCGGGCGCGGCGGCCCCCGGGCCTGGACTACTCCTTCGACACCTGCAAGCCGCCCGAGG
AGCAGCTCACCTTCAAGGACCTGGTGTCCTGTGCCTACCAGGTGGCCCGGGGCATGGAG
TACTTGGCCTCCCAGAAGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGAC
CGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTGGCCCGGGACGTGCACAACCTCG
ACTACTACAAGAAGACGACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGCC
TTGTTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCCTTTGGGGTCCTGCTCTG
GGAGATCTTCACGCTGGGGGGCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTTCA
AGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAACTGCACACACGACCTGTAC
ATGATCATGCGGGAGTGCTGGCATGCCGCGCCCTCCCAGAGGCCCACCTTCAAGCAGCT
GGTGGAGGACCTGGACCGTGTCCTTACCGTGACGTCCACCGACAATGTTATGGAACAGT
TCAATCCTGGGCTGCGAAATTTAATAAACCTGGGGAAAAATTATGAGAAAGCTGTAAAC
GCTATGATCCTGGCAGGAAAAGCCTACTACGATGGAGTGGCCAAGATCGGTGAGATTGC
CACTGGGTCCCCCGTGTCAACTGAACTGGGACATGTCCTCATAGAGATTTCAAGTACCC
ACAAGAAACTCAACGAGAGTCTTGATGAAAATTTTAAAAAATTCCACAAAGAGATTATC
CATGAGCTGGAGAAGAAGATAGAACTTGACGTGAAATATATGAACGCAACTCTAAAAAG
ATACCAAACAGAACACAAGAATAAATTAGAGTCTTTGGAGAAATCCCAAGCTGAGTTGA
AGAAGATCAGAAGGAAAAGCCAAGGAAGCCGAAACGCACTCAAATATGAACACAAAGAA
ATTGAGTATGTGGAGACCGTTACTTCTCGTCAGAGTGAAATCCAGAAATTCATTGCAGA
TGGTTGCAAAGAGGCTCTGCTTGAAGAGAAGAGGCGCTTCTGCTTTCTGGTTGATAAGC
ACTGTGGCTTTGCAAACCACATACATTATTATCACTTACAGTCTGCAGAACTACTGAAT
TCCAAGCTGCCTCGGTGGCAGGAGACCTGTGTTGATGCCATCAAAGTGCCAGAGAAAAT
CATGAATATGATCGAAGAAATAAAGACCCCAGCCTCTACCCCCGTGTCTGGAACTCCTC
AGGCTTCACCCATGATCGAGAGAAGCAATGTGGTTAGGAAAGATTACGACACCCTTTCT
AAATGCTCACCAAAGATGCCCCCCGCTCCTTCAGGCAGAGCATATACCAGTCCCTTGAT
CGATATGTTTAATAACCCAGCCACGGCTGCCCCGAATTCACAAAGGGTAAATAATTCAA
CAGGTACTTCCGAAGATCCCAGTTTACAGCGATCAGTTTCGGTTGCAACGGGACTGAAC
ATGATGAAGAAGCAGAAAGTGAAGACCATCTTCCCGCACACTGCGGGCTCCAACAAGAC
CTTACTCAGCTTTGCACAGGGAGATGTCATCACGCTGCTCATCCCCGAGGAGAAGGATG
GCTGGCTCTATGGAGAACACGACGTGTCCAAGGCGAGGGGTTGGTTCCCGTCGTCGTAC
ACGAAGTTGCTGGAAGAAAATGAGACAGAAGCAGTGACCGTGCCCACGCCAAGCCCCAC
ACCAGTGAGAAGCATCAGCACCGTGAACTTGTCTGAGAATAGCAGTGTTGTCATCCCCC
CACCCGACTACTTGGAATGCTTGTCCATGGGGGCAGCTGCCGACAGGAGAGCAGATTCG
GCCAGGACGACATCCACCTTTAAGGCCCCAGCGTCCAAGCCCGAGACCGCGGCTCCTAA
CGATGCCAACGGGACTGCAAAGCCGCCTTTTCTCAGCGGAGAAAACCCCTTTGCCACTG
TGAAACTCCGCCCGACTGTGACGAATGATCGCTCGGCACCCATCATTCGATGA FGFR2: BICC1
>ATGGTCAGCTGGGGTCGTTTCATCTGCCTGGTCGTGGTCACCATGGCAACCTTGTCCC
(4989 base pairs)
TGGCCCGGCCCTCCTTCAGTTTAGTTGAGGATACCACATTAGAGCCAGAAGAGCCACCA (SEQ ID
NO: 23) ACCAAATACCAAATCTCTCAACCAGAAGTGTACGTGGCTGCGCCAGGGGAGTCGCTAGA
GGTGCGCTGCCTGTTGAAAGATGCCGCCGTGATCAGTTGGACTAAGGATGGGGTGCACT
TGGGGCCCAACAATAGGACAGTGCTTATTGGGGAGTACTTGCAGATAAAGGGCGCCACG
CCTAGAGACTCCGGCCTCTATGCTTGTACTGCCAGTAGGACTGTAGACAGTGAAACTTG
GTACTTCATGGTGAATGTCACAGATGCCATCTCATCCGGAGATGATGAGGATGACACCG
ATGGTGCGGAAGATTTTGTCAGTGAGAACAGTAACAACAAGAGAGCACCATACTGGACC
AACACAGAAAAGATGGAAAAGCGGCTCCATGCTGTGCCTGCGGCCAACACTGTCAAGTT
TCGCTGCCCAGCCGGGGGGAACCCAATGCCAACCATGCGGTGGCTGAAAAACGGGAAGG
AGTTTAAGCAGGAGCATCGCATTGGAGGCTACAAGGTACGAAACCAGCACTGGAGCCTC
ATTATGGAAAGTGTGGTCCCATCTGACAAGGGAAATTATACCTGTGTAGTGGAGAATGA
ATACGGGTCCATCAATCACACGTACCACCTGGATGTTGTGGAGCGATCGCCTCACCGGC
CCATCCTCCAAGCCGGACTGCCGGCAAATGCCTCCACAGTGGTCGGAGGAGACGTAGAG
TTTGTCTGCAAGGTTTACAGTGATGCCCAGCCCCACATCCAGTGGATCAAGCACGTGGA
AAAGAACGGCAGTAAATACGGGCCCGACGGGCTGCCCTACCTCAAGGTTCTCAAGGCCG
CCGGTGTTAACACCACGGACAAAGAGATTGAGGTTCTCTATATTCGGAATGTAACTTTT
GAGGACGCTGGGGAATATACGTGCTTGGCGGGTAATTCTATTGGGATATCCTTTCACTC
TGCATGGTTGACAGTTCTGCCAGCGCCTGGAAGAGAAAAGGAGATTACAGCTTCCCCAG
ACTACCTGGAGATAGCCATTTACTGCATAGGGGTCTTCTTAATCGCCTGTATGGTGGTA
ACAGTCATCCTGTGCCGAATGAAGAACACGACCAAGAAGCCAGACTTCAGCAGCCAGCC
GGCTGTGCACAAGCTGACCAAACGTATCCCCCTGCGGAGACAGGTAACAGTTTCGGCTG
AGTCCAGCTCCTCCATGAACTCCAACACCCCGCTGGTGAGGATAACAACACGCCTCTCT
TCAACGGCAGACACCCCCATGCTGGCAGGGGTCTCCGAGTATGAACTTCCAGAGGACCC
AAAATGGGAGTTTCCAAGAGATAAGCTGACACTGGGCAAGCCCCTGGGAGAAGGTTGCT
TTGGGCAAGTGGTCATGGCGGAAGCAGTGGGAATTGACAAAGACAAGCCCAAGGAGGCG
GTCACCGTGGCCGTGAAGATGTTGAAAGATGATGCCACAGAGAAAGACCTTTCTGATCT
GGTGTCAGAGATGGAGATGATGAAGATGATTGGGAAACACAAGAATATCATAAATCTTC
TTGGAGCCTGCACACAGGATGGGCCTCTCTATGTCATAGTTGAGTATGCCTCTAAAGGC
AACCTCCGAGAATACCTCCGAGCCCGGAGGCCACCCGGGATGGAGTACTCCTATGACAT
TAACCGTGTTCCTGAGGAGCAGATGACCTTCAAGGACTTGGTGTCATGCACCTACCAGC
TGGCCAGAGGCATGGAGTACTTGGCTTCCCAAAAATGTATTCATCGAGATTTAGCAGCC
AGAAATGTTTTGGTAACAGAAAACAATGTGATGAAAATAGCAGACTTTGGACTCGCCAG
AGATATCAACAATATAGACTATTACAAAAAGACCACCAATGGGCGGCTTCCAGTCAAGT
GGATGGCTCCAGAAGCCCTGTTTGATAGAGTATACACTCATCAGAGTGATGTCTGGTCC
TTCGGGGTGTTAATGTGGGAGATCTTCACTTTAGGGGGCTCGCCCTACCCAGGGATTCC
CGTGGAGGAACTTTTTAAGCTGCTGAAGGAAGGACACAGAATGGATAAGCCAGCCAACT
GCACCAACGAACTGTACATGATGATGAGGGACTGTTGGCATGCAGTGCCCTCCCAGAGA
CCAACGTTCAAGCAGTTGGTAGAAGACTTGGATCGAATTCTCACTCTCACAACCAATGA
GATCATGGAGGAAACAAATACGCAGATTGCTTGGCCATCAAAACTGAAGATCGGAGCCA
AATCCAAGAAAGATCCCCATATTAAGGTTTCTGGAAAGAAAGAAGATGTTAAAGAAGCC
AAGGAAATGATCATGTCTGTCTTAGACACAAAAAGCAATCGAGTCACACTGAAGATGGA
TGTTTCACATACAGAACATTCACATGTAATCGGCAAAGGTGGCAACAATATTAAAAAAG
TGATGGAAGAAACCGGATGCCATATCCACTTTCCAGATTCCAACAGGAATAACCAAGCA
GAAAAAAGCAACCAGGTATCTATAGCGGGACAACCAGCAGGAGTAGAATCTGCCCGAGT
TAGAATTCGGGAGCTGCTTCCTTTGGTGCTGATGTTTGAGCTACCAATTGCTGGAATTC
TTCAACCGGTTCCTGATCCTAATTCCCCCTCTATTCAGCATATATCACAAACGTACAAT
ATTTCAGTATCATTTAAACAGCGTTCCCGAATGTATGGTGCTACTGTCATAGTACGAGG
GTCTCAGAATAACACTAGTGCTGTGAAGGAAGGAACTGCCATGCTGTTAGAACATCTTG
CTGGGAGCTTAGCATCAGCTATTCCTGTGAGCACACAACTAGATATTGCAGCTCAACAT
CATCTCTTTATGATGGGTCGAAATGGGAGCAACATCAAACATATCATGCAGAGAACAGG
TGCTCAGATCCACTTTCCTGATCCCAGTAATCCACAAAAGAAATCTACCGTCTACCTCC
AGGGCACCATTGAGTCTGTCTGTCTTGCAAGGCAATATCTCATGGGTTGTCTTCCTCTT
GTGTTGATGTTTGATATGAAGGAAGAAATTGAAGTAGATCCACAATTCATTGCGCAGTT
GATGGAACAGCTTGATGTCTTCATCAGTATTAAACCAAAGCCCAAACAGCCAAGCAAGT
CTGTGATTGTGAAAAGTGTTGAGCGAAATGCCTTAAATATGTATGAAGCAAGGAAATGT
CTCCTCGGACTTGAAAGCAGTGGGGTTACCATAGCAACCAGTCCATCCCCAGCATCCTG
CCCTGCCGGCCTGGCATGTCCCAGCCTGGATATCTTAGCTTCAGCAGGCCTTGGACTCA
CTGGACTAGGTCTTTTGGGACCCACCACCTTATCTCTGAACACTTCAACAACCCCAAAC
TCACTCTTGAATGCTCTTAATAGCTCAGTCAGTCCTTTGCAAAGTCCAAGTTCTGGTAC
ACCCAGCCCCACATTATGGGCACCCCCACTTGCTAATACTTCAAGTGCCACAGGTTTTT
CTGCTATACCACACCTTATGATTCCATCTACTGCCCAAGCCACATTAACTAATATTTTG
TTGTCTGGAGTGCCCACCTATGGGCACACAGCTCCATCTCCCCCTCCTGGCTTGACTCC
TGTTGATGTCCATATCAACAGTATGCAGACCGAAGGCAAAAAAATCTCTGCTGCTTTAA
ATGGACATGCACAGTCTCCAGATATAAAATATGGTGCAATATCCACTTCATCACTTGGA
GAAAAAGTGCTGAGTGCAAATCACGGGGATCCGTCCATCCAGACAAGTGGGTCTGAGCA
GACATCTCCCAAATCAAGCCCCACTGAAGGTTGTAATGATGCTTTTGTTGAAGTAGGCA
TGCCTCGAAGTCCTTCCCATTCTGGGAATGCTGGTGACTTGAAACAGATGATGTGTCCC
TCCAAGGTTTCCTGTGCCAAAAGGCAGACAGTGGAACTATTGCAAGGCACGAAAAACTC
ACACTTACACAGCACTGACAGGTTGCTCTCAGACCCTGAACTGAGTGCTACCGAAAGCC
CTTTGGCTGACAAGAAGGCTCCAGGGAGTGAGCGCGCTGCAGAGAGGGCAGCAGCTGCC
CAGCAAAACTCCGAAAGGGCCCACCTTGCTCCACGGTCATCATATGTCAACATGCAGGC
ATTTGACTATGAACAGAAGAAGCTATTAGCCACCAAAGCTATGTTAAAGAAACCAGTGG
TGACGGAGGTCAGAACGCCCACAAATACCTGGAGTGGCCTGGGTTTTTCTAAATCCATG
CCAGCTGAAACTATCAAGGAGTTGAGAAGGGCCAATCATGTGTCCTATAAGCCCACAAT
GACAACCACTTATGAGGGCTCATCCATGTCCCTTTCACGGTCCAACAGTCGTGAGCACT
TGGGAGGTGGAAGCGAATCTGATAACTGGAGAGACCGAAATGGAATTGGACCTGGAAGT
CATAGTGAATTTGCAGCTTCTATTGGCAGCCCTAAGCGTAAACAAAACAAATCAACGGA
ACACTATCTCAGCAGTAGCAATTACATGGACTGCATTTCCTCGCTGACAGGAAGCAATG
GCTGTAACTTAAATAGCTCTTTCAAAGGTTCTGACCTCCCTGAGCTCTTCAGCAAACTG
GGCCTGGGCAAATACACAGATGTTTTCCAGCAACAAGAGATCGATCTTCAGACATTCCT
CACTCTCACAGATCAGGATCTGAAGGAGCTGGGAATAACTACTTTTGGTGCCAGGAGGA
AAATGCTGCTTGCAATTTCAGAACTAAATAAAAACCGAAGAAAGCTTTTTGAATCGCCA
AATGCACGCACCTCTTTCCTGGAAGGTGGAGCGAGTGGAAGGCTACCCCGTCAGTATCA
CTCAGACATTGCTAGTGTCAGTGGCCGCTGGTAG FGFR2: AFF3
>ATGGTCAGCTGGGGTCGTTTCATCTGCCTGGTCGTGGTCACCATGGCAACCTTGTCCC
(5109 base pairs)
TGGCCCGGCCCTCCTTCAGTTTAGTTGAGGATACCACATTAGAGCCAGAAGAGCCACCA (SEQ ID
NO: 24) ACCAAATACCAAATCTCTCAACCAGAAGTGTACGTGGCTGCGCCAGGGGAGTCGCTAGA
GGTGCGCTGCCTGTTGAAAGATGCCGCCGTGATCAGTTGGACTAAGGATGGGGTGCACT
TGGGGCCCAACAATAGGACAGTGCTTATTGGGGAGTACTTGCAGATAAAGGGCGCCACG
CCTAGAGACTCCGGCCTCTATGCTTGTACTGCCAGTAGGACTGTAGACAGTGAAACTTG
GTACTTCATGGTGAATGTCACAGATGCCATCTCATCCGGAGATGATGAGGATGACACCG
ATGGTGCGGAAGATTTTGTCAGTGAGAACAGTAACAACAAGAGAGCACCATACTGGACC
AACACAGAAAAGATGGAAAAGCGGCTCCATGCTGTGCCTGCGGCCAACACTGTCAAGTT
TCGCTGCCCAGCCGGGGGGAACCCAATGCCAACCATGCGGTGGCTGAAAAACGGGAAGG
AGTTTAAGCAGGAGCATCGCATTGGAGGCTACAAGGTACGAAACCAGCACTGGAGCCTC
ATTATGGAAAGTGTGGTCCCATCTGACAAGGGAAATTATACCTGTGTAGTGGAGAATGA
ATACGGGTCCATCAATCACACGTACCACCTGGATGTTGTGGAGCGATCGCCTCACCGGC
CCATCCTCCAAGCCGGACTGCCGGCAAATGCCTCCACAGTGGTCGGAGGAGACGTAGAG
TTTGTCTGCAAGGTTTACAGTGATGCCCAGCCCCACATCCAGTGGATCAAGCACGTGGA
AAAGAACGGCAGTAAATACGGGCCCGACGGGCTGCCCTACCTCAAGGTTCTCAAGGCCG
CCGGTGTTAACACCACGGACAAAGAGATTGAGGTTCTCTATATTCGGAATGTAACTTTT
GAGGACGCTGGGGAATATACGTGCTTGGCGGGTAATTCTATTGGGATATCCTTTCACTC
TGCATGGTTGACAGTTCTGCCAGCGCCTGGAAGAGAAAAGGAGATTACAGCTTCCCCAG
ACTACCTGGAGATAGCCATTTACTGCATAGGGGTCTTCTTAATCGCCTGTATGGTGGTA
ACAGTCATCCTGTGCCGAATGAAGAACACGACCAAGAAGCCAGACTTCAGCAGCCAGCC
GGCTGTGCACAAGCTGACCAAACGTATCCCCCTGCGGAGACAGGTAACAGTTTCGGCTG
AGTCCAGCTCCTCCATGAACTCCAACACCCCGCTGGTGAGGATAACAACACGCCTCTCT
TCAACGGCAGACACCCCCATGCTGGCAGGGGTCTCCGAGTATGAACTTCCAGAGGACCC
AAAATGGGAGTTTCCAAGAGATAAGCTGACACTGGGCAAGCCCCTGGGAGAAGGTTGCT
TTGGGCAAGTGGTCATGGCGGAAGCAGTGGGAATTGACAAAGACAAGCCCAAGGAGGCG
GTCACCGTGGCCGTGAAGATGTTGAAAGATGATGCCACAGAGAAAGACCTTTCTGATCT
GGTGTCAGAGATGGAGATGATGAAGATGATTGGGAAACACAAGAATATCATAAATCTTC
TTGGAGCCTGCACACAGGATGGGCCTCTCTATGTCATAGTTGAGTATGCCTCTAAAGGC
AACCTCCGAGAATACCTCCGAGCCCGGAGGCCACCCGGGATGGAGTACTCCTATGACAT
TAACCGTGTTCCTGAGGAGCAGATGACCTTCAAGGACTTGGTGTCATGCACCTACCAGC
TGGCCAGAGGCATGGAGTACTTGGCTTCCCAAAAATGTATTCATCGAGATTTAGCAGCC
AGAAATGTTTTGGTAACAGAAAACAATGTGATGAAAATAGCAGACTTTGGACTCGCCAG
AGATATCAACAATATAGACTATTACAAAAAGACCACCAATGGGCGGCTTCCAGTCAAGT
GGATGGCTCCAGAAGCCCTGTTTGATAGAGTATACACTCATCAGAGTGATGTCTGGTCC
TTCGGGGTGTTAATGTGGGAGATCTTCACTTTAGGGGGCTCGCCCTACCCAGGGATTCC
CGTGGAGGAACTTTTTAAGCTGCTGAAGGAAGGACACAGAATGGATAAGCCAGCCAACT
GCACCAACGAACTGTACATGATGATGAGGGACTGTTGGCATGCAGTGCCCTCCCAGAGA
CCAACGTTCAAGCAGTTGGTAGAAGACTTGGATCGAATTCTCACTCTCACAACCAATGA
GGAGAGTAGATCTGGAGAAACCAACAGCTGTGTTGAAGAAATAATCCGGGAGATGACCT
GGCTTCCACCACTTTCTGCTATTCAAGCACCTGGCAAAGTGGAACCAACCAAATTTCCA
TTTCCAAATAAGGACTCTCAGCTTGTATCCTCTGGACACAATAATCCAAAGAAAGGTGA
TGCAGAGCCAGAGAGTCCAGACAGTGGCACATCGAATACATCAATGCTGGAAGATGACC
TTAAGCTAAGCAGTGATGAAGAGGAGAATGAACAGCAGGCAGCTCAGAGAACGGCTCTC
CGCGCTCTCTCTGACAGCGCCGTGGTCCAGCAGCCCAACTGCAGAACCTCGGTGCCTTC
CAGCAAGGGCAGCAGCAGCAGCAGCAGCAGCGGCAGCAGCAGCTCCTCCAGCGACTCAG
AGAGCAGCTCCGGATCTGACTCGGAGACCGAGAGCAGCTCCAGCGAGAGTGAGGGCAGC
AAGCCCCCCCACTTCTCCAGCCCCGAGGCTGAACCGGCATCCTCTAACAAGTGGCAGCT
GGATAAATGGCTAAACAAAGTTAATCCCCACAAGCCTCCTATTCTGATCCAAAATGAAA
GCCACGGGTCAGAGAGCAATCAGTACTACAACCCGGTGAAAGAGGACGTCCAGGACTGT
GGGAAAGTCCCCGACGTTTGCCAGCCCAGCCTGAGAGAGAAGGAGATCAAGAGCACTTG
CAAGGAGGAGCAAAGGCCAAGGACAGCCAACAAGGCCCCTGGGAGTAAAGGCGTGAAGC
AGAAGTCCCCGCCCGCGGCCGTGGCCGTGGCGGTGAGCGCAGCCGCCCCGCCACCCGCA
GTGCCCTGTGCGCCCGCGGAGAACGCGCCCGCGCCTGCCCGGAGGTCCGCGGGCAAGAA
GCCCACCAGGCGCACCGAGAGGACCTCAGCCGGGGACGGCGCCAACTGCCACCGGCCCG
AGGAGCCCGCGGCCGCGGACGCGCTGGGGACGAGCGTGGTGGTCCCCCCGGAGCCCACC
AAAACCAGGCCCTGTGGCAACAACAGAGCGAGCCACCGCAAGGAGCTGCGCTCCTCCGT
GACCTGCGAGAAGCGCCGCACGCGGGGGCTAAGCAGGATCGTCCCCAAATCCAAGGAGT
TCATTGAGACAGAGTCGTCATCTTCATCCTCCTCCTCGGACTCCGACCTGGAGTCCGAG
CAGGAGGAGTACCCTCTGTCCAAAGCACAGACCGTGGCTGCCTCTGCCTCCTCCGGGAA
TGATCAGAGGCTGAAGGAGGCCGCTGCCAACGGGGGCAGTGGTCCTAGGGCCCCTGTAG
GCTCCATCAACGCCAGGACCACCAGTGACATCGCCAAGGAGCTGGAGGAGCAGTTCTAC
ACACTGGTCCCCTTTGGCCGGAACGAACTTCTCTCCCCTCTAAAGGACAGTGATGAGAT
CAGGTCTCTCTGGGTCAAAATCGACCTGACCCTCCTGTCCAGGATCCCAGAACACCTGC
CCCAGGAGCCAGGGGTATTGAGCGCCCCTGCCACCAAGGACTCTGAGAGCGCACCGCCC
AGCCACACCTCGGACACACCTGCAGAAAAGGCTTTGCCAAAATCCAAGAGGAAACGCAA
GTGTGACAACGAAGACGACTACAGGGAGATCAAGAAGTCCCAGGGAGAGAAAGACAGCT
CTTCAAGACTGGCCACCTCCACCAGTAATACTTTGTCTGCAAACCACTGCAACATGAAC
ATCAACAGTGTGGCAATACCAATAAATAAAAATGAAAAAATGCTTCGGTCGCCCATCTC
ACCCCTCTCTGATGCATCTAAACACAAATACACCAGCGAGGACTTAACTTCTTCCAGCC
GACCTAATGGCAACAGTTTGTTTACTTCAGCCTCTTCCAGCAAAAAGCCTAAGGCCGAC
AGCCAGCTGCAGCCTCACGGCGGAGACCTCACGAAAGCAGCTCACAACAATTCTGAAAA
CATTCCCCTCCACAAGTCACGGCCGCAGACGAAGCCGTGGTCTCCAGGCTCCAACGGCC
ACAGGGACTGCAAGAGGCAGAAACTTGTCTTCGATGATATGCCTCGCAGTGCCGATTAT
TTTATGCAAGAAGCTAAACGAATGAAGCATAAAGCAGATGCAATGGTGGAAAAGTTTGG
AAAGGCTTTGAACTATGCTGAAGCAGCATTGTCGTTTATCGAGTGTGGAAATGCAATGG
AACAAGGCCCCATGGAATCCAAATCTCCTTATACGATGTATTCAGAAACAGTAGAGCTC
ATCAGGTATGCTATGAGACTAAAAACCCACTCAGGCCCCAATGCCACACCAGAAGACAA
ACAACTGGCTGCATTATGTTACCGATGCCTGGCCCTCCTGTACTGGCGGATGTTTCGAC
TCAAAAGGGACCACGCTGTAAAGTATTCAAAAGCACTAATCGACTATTTCAAGAACTCA
TCTAAAGCCGCCCAAGCCCCATCTCCGTGGGGGGCCAGTGGAAAGAGCACTGGAACCCC
ATCCCCCATGTCTCCCAACCCCTCTCCCGCCAGCTCCGTGGGGTCTCAGGGCAGCCTCT
CCAACGCCAGCGCCCTGTCCCCGTCGACCATCGTCAGCATCCCACAGCGCATCCACCAG
ATGGCGGCCAACCACGTCAGCATCACCAACAGCATCCTGCACAGCTACGACTACTGGGA
GATGGCCGACAACCTGGCCAAGGAAAACCGAGAATTCTTCAACGACCTGGATCTGCTCA
TGGGGCCGGTCACCCTGCACAGCAGCATGGAGCACCTGGTCCAGTACTCCCAACAGGGC
CTGCACTGGCTGCGGAACAGCGCCCACCTGTCATAG FGFR2: CASP7
>ATGGTCAGCTGGGGTCGTTTCATCTGCCTGGTCGTGGTCACCATGGCAACCTTGTCCC
(3213 base pairs)
TGGCCCGGCCCTCCTTCAGTTTAGTTGAGGATACCACATTAGAGCCAGAAGAGCCACCA (SEQ ID
NO: 25) ACCAAATACCAAATCTCTCAACCAGAAGTGTACGTGGCTGCGCCAGGGGAGTCGCTAGA
GGTGCGCTGCCTGTTGAAAGATGCCGCCGTGATCAGTTGGACTAAGGATGGGGTGCACT
TGGGGCCCAACAATAGGACAGTGCTTATTGGGGAGTACTTGCAGATAAAGGGCGCCACG
CCTAGAGACTCCGGCCTCTATGCTTGTACTGCCAGTAGGACTGTAGACAGTGAAACTTG
GTACTTCATGGTGAATGTCACAGATGCCATCTCATCCGGAGATGATGAGGATGACACCG
ATGGTGCGGAAGATTTTGTCAGTGAGAACAGTAACAACAAGAGAGCACCATACTGGACC
AACACAGAAAAGATGGAAAAGCGGCTCCATGCTGTGCCTGCGGCCAACACTGTCAAGTT
TCGCTGCCCAGCCGGGGGGAACCCAATGCCAACCATGCGGTGGCTGAAAAACGGGAAGG
AGTTTAAGCAGGAGCATCGCATTGGAGGCTACAAGGTACGAAACCAGCACTGGAGCCTC
ATTATGGAAAGTGTGGTCCCATCTGACAAGGGAAATTATACCTGTGTAGTGGAGAATGA
ATACGGGTCCATCAATCACACGTACCACCTGGATGTTGTGGAGCGATCGCCTCACCGGC
CCATCCTCCAAGCCGGACTGCCGGCAAATGCCTCCACAGTGGTCGGAGGAGACGTAGAG
TTTGTCTGCAAGGTTTACAGTGATGCCCAGCCCCACATCCAGTGGATCAAGCACGTGGA
AAAGAACGGCAGTAAATACGGGCCCGACGGGCTGCCCTACCTCAAGGTTCTCAAGGCCG
CCGGTGTTAACACCACGGACAAAGAGATTGAGGTTCTCTATATTCGGAATGTAACTTTT
GAGGACGCTGGGGAATATACGTGCTTGGCGGGTAATTCTATTGGGATATCCTTTCACTC
TGCATGGTTGACAGTTCTGCCAGCGCCTGGAAGAGAAAAGGAGATTACAGCTTCCCCAG
ACTACCTGGAGATAGCCATTTACTGCATAGGGGTCTTCTTAATCGCCTGTATGGTGGTA
ACAGTCATCCTGTGCCGAATGAAGAACACGACCAAGAAGCCAGACTTCAGCAGCCAGCC
GGCTGTGCACAAGCTGACCAAACGTATCCCCCTGCGGAGACAGGTAACAGTTTCGGCTG
AGTCCAGCTCCTCCATGAACTCCAACACCCCGCTGGTGAGGATAACAACACGCCTCTCT
TCAACGGCAGACACCCCCATGCTGGCAGGGGTCTCCGAGTATGAACTTCCAGAGGACCC
AAAATGGGAGTTTCCAAGAGATAAGCTGACACTGGGCAAGCCCCTGGGAGAAGGTTGCT
TTGGGCAAGTGGTCATGGCGGAAGCAGTGGGAATTGACAAAGACAAGCCCAAGGAGGCG
GTCACCGTGGCCGTGAAGATGTTGAAAGATGATGCCACAGAGAAAGACCTTTCTGATCT
GGTGTCAGAGATGGAGATGATGAAGATGATTGGGAAACACAAGAATATCATAAATCTTC
TTGGAGCCTGCACACAGGATGGGCCTCTCTATGTCATAGTTGAGTATGCCTCTAAAGGC
AACCTCCGAGAATACCTCCGAGCCCGGAGGCCACCCGGGATGGAGTACTCCTATGACAT
TAACCGTGTTCCTGAGGAGCAGATGACCTTCAAGGACTTGGTGTCATGCACCTACCAGC
TGGCCAGAGGCATGGAGTACTTGGCTTCCCAAAAATGTATTCATCGAGATTTAGCAGCC
AGAAATGTTTTGGTAACAGAAAACAATGTGATGAAAATAGCAGACTTTGGACTCGCCAG
AGATATCAACAATATAGACTATTACAAAAAGACCACCAATGGGCGGCTTCCAGTCAAGT
GGATGGCTCCAGAAGCCCTGTTTGATAGAGTATACACTCATCAGAGTGATGTCTGGTCC
TTCGGGGTGTTAATGTGGGAGATCTTCACTTTAGGGGGCTCGCCCTACCCAGGGATTCC
CGTGGAGGAACTTTTTAAGCTGCTGAAGGAAGGACACAGAATGGATAAGCCAGCCAACT
GCACCAACGAACTGTACATGATGATGAGGGACTGTTGGCATGCAGTGCCCTCCCAGAGA
CCAACGTTCAAGCAGTTGGTAGAAGACTTGGATCGAATTCTCACTCTCACAACCAATGA
GATGGCAGATGATCAGGGCTGTATTGAAGAGCAGGGGGTTGAGGATTCAGCAAATGAAG
ATTCAGTGGATGCTAAGCCAGACCGGTCCTCGTTTGTACCGTCCCTCTTCAGTAAGAAG
AAGAAAAATGTCACCATGCGATCCATCAAGACCACCCGGGACCGAGTGCCTACATATCA
GTACAACATGAATTTTGAAAAGCTGGGCAAATGCATCATAATAAACAACAAGAACTTTG
ATAAAGTGACAGGTATGGGCGTTCGAAACGGAACAGACAAAGATGCCGAGGCGCTCTTC
AAGTGCTTCCGAAGCCTGGGTTTTGACGTGATTGTCTATAATGACTGCTCTTGTGCCAA
GATGCAAGATCTGCTTAAAAAAGCTTCTGAAGAGGACCATACAAATGCCGCCTGCTTCG
CCTGCATCCTCTTAAGCCATGGAGAAGAAAATGTAATTTATGGGAAAGATGGTGTCACA
CCAATAAAGGATTTGACAGCCCACTTTAGGGGGGATAGATGCAAAACCCTTTTAGAGAA
ACCCAAACTCTTCTTCATTCAGGCTTGCCGAGGGACCGAGCTTGATGATGGCATCCAGG
CCGACTCGGGGCCCATCAATGACACAGATGCTAATCCTCGATACAAGATCCCAGTGGAA
GCTGACTTCCTCTTCGCCTATTCCACGGTTCCAGGCTATTACTCGTGGAGGAGCCCAGG
AAGAGGCTCCTGGTTTGTGCAAGCCCTCTGCTCCATCCTGGAGGAGCACGGAAAAGACC
TGGAAATCATGCAGATCCTCACCAGGGTGAATGACAGAGTTGCCAGGCACTTTGAGTCT
CAGTCTGATGACCCACACTTCCATGAGAAGAAGCAGATCCCCTGTGTGGTCTCCATGCT
CACCAAGGAACTCTACTTCAGTCAATAG FGFR2: CCDC6
>ATGGTCAGCTGGGGTCGTTTCATCTGCCTGGTCGTGGTCACCATGGCAACCTTGTCCC
(3423 base pairs)
TGGCCCGGCCCTCCTTCAGTTTAGTTGAGGATACCACATTAGAGCCAGAAGAGCCACCA (SEQ ID
NO: 26)
ACCAAATACCAAATCTCTCAACCAGAAGTGTACGTGGCTGCGCCAGGGGAGTCGCTAGA
GGTGCGCTGCCTGTTGAAAGATGCCGCCGTGATCAGTTGGACTAAGGATGGGGTGCACT
TGGGGCCCAACAATAGGACAGTGCTTATTGGGGAGTACTTGCAGATAAAGGGCGCCACG
CCTAGAGACTCCGGCCTCTATGCTTGTACTGCCAGTAGGACTGTAGACAGTGAAACTTG
GTACTTCATGGTGAATGTCACAGATGCCATCTCATCCGGAGATGATGAGGATGACACCG
ATGGTGCGGAAGATTTTGTCAGTGAGAACAGTAACAACAAGAGAGCACCATACTGGACC
AACACAGAAAAGATGGAAAAGCGGCTCCATGCTGTGCCTGCGGCCAACACTGTCAAGTT
TCGCTGCCCAGCCGGGGGGAACCCAATGCCAACCATGCGGTGGCTGAAAAACGGGAAGG
AGTTTAAGCAGGAGCATCGCATTGGAGGCTACAAGGTACGAAACCAGCACTGGAGCCTC
ATTATGGAAAGTGTGGTCCCATCTGACAAGGGAAATTATACCTGTGTAGTGGAGAATGA
ATACGGGTCCATCAATCACACGTACCACCTGGATGTTGTGGAGCGATCGCCTCACCGGC
CCATCCTCCAAGCCGGACTGCCGGCAAATGCCTCCACAGTGGTCGGAGGAGACGTAGAG
TTTGTCTGCAAGGTTTACAGTGATGCCCAGCCCCACATCCAGTGGATCAAGCACGTGGA
AAAGAACGGCAGTAAATACGGGCCCGACGGGCTGCCCTACCTCAAGGTTCTCAAGGCCG
CCGGTGTTAACACCACGGACAAAGAGATTGAGGTTCTCTATATTCGGAATGTAACTTTT
GAGGACGCTGGGGAATATACGTGCTTGGCGGGTAATTCTATTGGGATATCCTTTCACTC
TGCATGGTTGACAGTTCTGCCAGCGCCTGGAAGAGAAAAGGAGATTACAGCTTCCCCAG
ACTACCTGGAGATAGCCATTTACTGCATAGGGGTCTTCTTAATCGCCTGTATGGTGGTA
ACAGTCATCCTGTGCCGAATGAAGAACACGACCAAGAAGCCAGACTTCAGCAGCCAGCC
GGCTGTGCACAAGCTGACCAAACGTATCCCCCTGCGGAGACAGGTAACAGTTTCGGCTG
AGTCCAGCTCCTCCATGAACTCCAACACCCCGCTGGTGAGGATAACAACACGCCTCTCT
TCAACGGCAGACACCCCCATGCTGGCAGGGGTCTCCGAGTATGAACTTCCAGAGGACCC
AAAATGGGAGTTTCCAAGAGATAAGCTGACACTGGGCAAGCCCCTGGGAGAAGGTTGCT
TTGGGCAAGTGGTCATGGCGGAAGCAGTGGGAATTGACAAAGACAAGCCCAAGGAGGCG
GTCACCGTGGCCGTGAAGATGTTGAAAGATGATGCCACAGAGAAAGACCTTTCTGATCT
GGTGTCAGAGATGGAGATGATGAAGATGATTGGGAAACACAAGAATATCATAAATCTTC
TTGGAGCCTGCACACAGGATGGGCCTCTCTATGTCATAGTTGAGTATGCCTCTAAAGGC
AACCTCCGAGAATACCTCCGAGCCCGGAGGCCACCCGGGATGGAGTACTCCTATGACAT
TAACCGTGTTCCTGAGGAGCAGATGACCTTCAAGGACTTGGTGTCATGCACCTACCAGC
TGGCCAGAGGCATGGAGTACTTGGCTTCCCAAAAATGTATTCATCGAGATTTAGCAGCC
AGAAATGTTTTGGTAACAGAAAACAATGTGATGAAAATAGCAGACTTTGGACTCGCCAG
AGATATCAACAATATAGACTATTACAAAAAGACCACCAATGGGCGGCTTCCAGTCAAGT
GGATGGCTCCAGAAGCCCTGTTTGATAGAGTATACACTCATCAGAGTGATGTCTGGTCC
TTCGGGGTGTTAATGTGGGAGATCTTCACTTTAGGGGGCTCGCCCTACCCAGGGATTCC
CGTGGAGGAACTTTTTAAGCTGCTGAAGGAAGGACACAGAATGGATAAGCCAGCCAACT
GCACCAACGAACTGTACATGATGATGAGGGACTGTTGGCATGCAGTGCCCTCCCAGAGA
CCAACGTTCAAGCAGTTGGTAGAAGACTTGGATCGAATTCTCACTCTCACAACCAATGA
GCAAGCCAGGGCTGAGCAGGAAGAAGAATTCATTAGTAACACTTTATTCAAGAAAATTC
AGGCTTTGCAGAAGGAGAAAGAAACCCTTGCTGTAAATTATGAGAAAGAAGAAGAATTC
CTCACTAATGAGCTCTCCAGAAAATTGATGCAGTTGCAGCATGAGAAAGCCGAACTAGA
ACAGCATCTTGAACAAGAGCAGGAATTTCAGGTCAACAAACTGATGAAGAAAATTAAAA
AACTGGAGAATGACACCATTTCTAAGCAACTTACATTAGAACAGTTGAGACGGGAGAAG
ATTGACCTTGAAAATACATTGGAACAAGAACAAGAAGCACTAGTTAATCGCCTCTGGAA
AAGGATGGATAAGCTTGAAGCTGAAAAGCGAATCCTGCAGGAAAAATTAGACCAGCCCG
TCTCTGCTCCACCATCGCCTAGAGATATCTCCATGGAGATTGATTCTCCAGAAAATATG
ATGCGTCACATCAGGTTTTTAAAGAATGAAGTGGAACGGCTGAAGAAGCAACTGAGAGC
TGCTCAGTTACAGCATTCAGAGAAAATGGCACAGTATCTGGAGGAGGAACGTCACATGA
GAGAAGAGAACTTGAGGCTCCAGAGGAAGCTGCAGAGGGAGATGGAGAGAAGAGAAGCC
CTCTGTCGACAGCTCTCCGAGAGTGAGTCCAGCTTAGAAATGGACGACGAAAGGTATTT
TAATGAGATGTCTGCACAAGGATTAAGACCTCGCACTGTGTCCAGCCCGATCCCTTACA
CACCTTCTCCGAGTTCAAGCAGGCCTATATCACCTGGTCTATCATATGCAAGTCACACG
GTTGGTTTCACGCCACCAACTTCACTGACTAGAGCTGGAATGTCTTATTACAATTCCCC
GGGTCTTCACGTGCAGCACATGGGAACATCCCATGGTATCACAAGGCCTTCACCACGGA
GAAGCAACAGTCCTGACAAATTCAAACGGCCCACGCCGCCTCCATCTCCCAACACACAG
ACCCCAGTCCAGCCACCTCCGCCTCCACCTCCGCCACCCATGCAGCCCACGGTCCCCTC
AGCAGCCACCTCGCAGCCTACTCCTTCGCAACATTCGGCGCACCCCTCCTCCCAGCCTT AA
FGFR2: OFD1
>ATGGTCAGCTGGGGTCGTTTCATCTGCCTGGTCGTGGTCACCATGGCAACCTTGTCCC
(5229 base pairs)
TGGCCCGGCCCTCCTTCAGTTTAGTTGAGGATACCACATTAGAGCCAGAAGAGCCACCA (SEQ ID
NO: 27) ACCAAATACCAAATCTCTCAACCAGAAGTGTACGTGGCTGCGCCAGGGGAGTCGCTAGA
GGTGCGCTGCCTGTTGAAAGATGCCGCCGTGATCAGTTGGACTAAGGATGGGGTGCACT
TGGGGCCCAACAATAGGACAGTGCTTATTGGGGAGTACTTGCAGATAAAGGGCGCCACG
CCTAGAGACTCCGGCCTCTATGCTTGTACTGCCAGTAGGACTGTAGACAGTGAAACTTG
GTACTTCATGGTGAATGTCACAGATGCCATCTCATCCGGAGATGATGAGGATGACACCG
ATGGTGCGGAAGATTTTGTCAGTGAGAACAGTAACAACAAGAGAGCACCATACTGGACC
AACACAGAAAAGATGGAAAAGCGGCTCCATGCTGTGCCTGCGGCCAACACTGTCAAGTT
TCGCTGCCCAGCCGGGGGGAACCCAATGCCAACCATGCGGTGGCTGAAAAACGGGAAGG
AGTTTAAGCAGGAGCATCGCATTGGAGGCTACAAGGTACGAAACCAGCACTGGAGCCTC
ATTATGGAAAGTGTGGTCCCATCTGACAAGGGAAATTATACCTGTGTAGTGGAGAATGA
ATACGGGTCCATCAATCACACGTACCACCTGGATGTTGTGGAGCGATCGCCTCACCGGC
CCATCCTCCAAGCCGGACTGCCGGCAAATGCCTCCACAGTGGTCGGAGGAGACGTAGAG
TTTGTCTGCAAGGTTTACAGTGATGCCCAGCCCCACATCCAGTGGATCAAGCACGTGGA
AAAGAACGGCAGTAAATACGGGCCCGACGGGCTGCCCTACCTCAAGGTTCTCAAGGCCG
CCGGTGTTAACACCACGGACAAAGAGATTGAGGTTCTCTATATTCGGAATGTAACTTTT
GAGGACGCTGGGGAATATACGTGCTTGGCGGGTAATTCTATTGGGATATCCTTTCACTC
TGCATGGTTGACAGTTCTGCCAGCGCCTGGAAGAGAAAAGGAGATTACAGCTTCCCCAG
ACTACCTGGAGATAGCCATTTACTGCATAGGGGTCTTCTTAATCGCCTGTATGGTGGTA
ACAGTCATCCTGTGCCGAATGAAGAACACGACCAAGAAGCCAGACTTCAGCAGCCAGCC
GGCTGTGCACAAGCTGACCAAACGTATCCCCCTGCGGAGACAGGTAACAGTTTCGGCTG
AGTCCAGCTCCTCCATGAACTCCAACACCCCGCTGGTGAGGATAACAACACGCCTCTCT
TCAACGGCAGACACCCCCATGCTGGCAGGGGTCTCCGAGTATGAACTTCCAGAGGACCC
AAAATGGGAGTTTCCAAGAGATAAGCTGACACTGGGCAAGCCCCTGGGAGAAGGTTGCT
TTGGGCAAGTGGTCATGGCGGAAGCAGTGGGAATTGACAAAGACAAGCCCAAGGAGGCG
GTCACCGTGGCCGTGAAGATGTTGAAAGATGATGCCACAGAGAAAGACCTTTCTGATCT
GGTGTCAGAGATGGAGATGATGAAGATGATTGGGAAACACAAGAATATCATAAATCTTC
TTGGAGCCTGCACACAGGATGGGCCTCTCTATGTCATAGTTGAGTATGCCTCTAAAGGC
AACCTCCGAGAATACCTCCGAGCCCGGAGGCCACCCGGGATGGAGTACTCCTATGACAT
TAACCGTGTTCCTGAGGAGCAGATGACCTTCAAGGACTTGGTGTCATGCACCTACCAGC
TGGCCAGAGGCATGGAGTACTTGGCTTCCCAAAAATGTATTCATCGAGATTTAGCAGCC
AGAAATGTTTTGGTAACAGAAAACAATGTGATGAAAATAGCAGACTTTGGACTCGCCAG
AGATATCAACAATATAGACTATTACAAAAAGACCACCAATGGGCGGCTTCCAGTCAAGT
GGATGGCTCCAGAAGCCCTGTTTGATAGAGTATACACTCATCAGAGTGATGTCTGGTCC
TTCGGGGTGTTAATGTGGGAGATCTTCACTTTAGGGGGCTCGCCCTACCCAGGGATTCC
CGTGGAGGAACTTTTTAAGCTGCTGAAGGAAGGACACAGAATGGATAAGCCAGCCAACT
GCACCAACGAACTGTACATGATGATGAGGGACTGTTGGCATGCAGTGCCCTCCCAGAGA
CCAACGTTCAAGCAGTTGGTAGAAGACTTGGATCGAATTCTCACTCTCACAACCAATGA
GACACAACTTCGAAACCAGCTAATTCATGAGTTGATGCACCCTGTATTGAGTGGAGAAC
TGCAGCCTCGGTCCATTTCAGTAGAAGGGAGCTCCCTCTTAATAGGCGCCTCTAACTCT
TTAGTGGCAGATCACTTACAAAGATGTGGCTATGAATATTCACTTTCTGTTTTCTTTCC
AGAAAGTGGTTTGGCAAAAGAAAAGGTATTTACTATGCAGGATCTATTACAACTCATTA
AAATCAACCCTACTTCCAGTCTCTACAAATCACTGGTTTCAGGATCTGATAAAGAAAAT
CAAAAAGGTTTTCTTATGCATTTTTTAAAAGAATTGGCAGAATATCATCAAGCTAAAGA
GAGTTGTAATATGGAAACTCAGACAAGTTCGACATTTAACAGAGATTCTCTGGCTGAGA
AGCTTCAGCTTATTGATGATCAGTTTGCAGATGCTTACCCTCAGCGTATCAAGTTCGAA
TCTTTAGAAATAAAGCTAAATGAGTATAAGAGAGAAATAGAAGAGCAACTTCGGGCAGA
AATGTGTCAAAAGTTGAAGTTTTTTAAAGATACCGAGATAGCAAAAATTAAAATGGAAG
CAAAAAAAAAGTATGAAAAGGAGTTAACCATGTTCCAGAATGATTTTGAAAAAGCTTGT
CAAGCAAAATCTGAAGCTCTCGTTCTTCGGGAAAAGAGTACCCTTGAAAGAATTCACAA
GCACCAAGAGATTGAAACAAAAGAAATTTATGCTCAAAGGCAACTTTTACTAAAAGATA
TGGATTTGCTAAGAGGAAGAGAAGCAGAGCTGAAGCAAAGAGTTGAAGCTTTTGAATTG
AACCAGAAGCTCCAGGAAGAAAAACATAAAAGCATAACTGAGGCACTTAGGAGACAGGA
GCAGAATATAAAGAGTTTTGAGGAGACCTATGACCGAAAGCTCAAGAATGAACTTCTAA
AGTATCAACTTGAACTGAAGGATGACTACATCATTAGAACTAATCGACTGATTGAAGAT
GAAAGGAAGAATAAAGAAAAAGCTGTTCATTTGCAAGAGGAGCTCATAGCTATTAATTC
AAAAAAGGAGGAACTCAATCAATCTGTAAATCGTGTGAAAGAACTTGAGCTTGAATTAG
AGTCTGTCAAAGCCCAGTCTTTGGCAATAACAAAACAAAACCATATGCTGAATGAAAAG
GTTAAAGAGATGAGTGATTATTCACTACTAAAAGAAGAGAAACTGGAGCTTCTGGCACA
AAATAAATTACTTAAACAACAACTGGAAGAGAGTAGAAATGAAAACCTGCGTCTCCTAA
ACCGCCTAGCTCAGCCGGCTCCTGAACTTGCAGTCTTTCAGAAAGAACTACGGAAAGCC
GAAAAGGCTATAGTGGTTGAGCATGAGGAGTTCGAAAGCTGCAGGCAAGCTCTGCACAA
ACAACTGCAAGACGAAATTGAGCATTCTGCACAGCTGAAGGCCCAGATTCTAGGTTACA
AAGCTTCTGTAAAGAGTTTAACTACTCAGGTTGCCGATTTAAAATTGCAACTGAAGCAA
ACTCAGACAGCCCTAGAGAATGAAGTGTACTGCAATCCAAAGCAGTCTGTGATCGATCG
TTCTGTCAATGGATTAATAAATGGCAATGTGGTGCCTTGCAATGGTGAGATAAGTGGGG
ATTTCTTGAACAATCCTTTTAAACAGGAAAACGTTCTAGCACGTATGGTTGCATCAAGG
ATCACAAATTATCCAACTGCATGGGTGGAGGGTAGTTCCCCTGATTCTGACCTTGAGTT
TGTAGCCAATACTAAGGCAAGGGTCAAAGAGCTTCAGCAAGAGGCCGAACGCTTGGAAA
AGGCTTTCAGAAGTTACCATCGGAGAGTCATTAAAAACTCTGCCAAAAGCCCACTAGCA
GCAAAGAGCCCACCATCTCTGCACTTGCTGGAAGCCTTCAAAAACATTACTTCCAGTTC
CCCGGAAAGACATATTTTTGGAGAGGACAGAGTTGTCTCTGAGCAGCCTCAAGTGGGCA
CACTTGAAGAAAGGAATGACGTCGTGGAAGCACTGACAGGCAGTGCAGCCTCGAGGCTC
CGCGGGGGCACTTCCTCCAGACGCCTCTCTTCCACACCCCTTCCAAAAGCAAAAAGAAG
CCTCGAAAGTGAAATGTATCTGGAAGGTCTGGGCAGATCACACATTGCTTCCCCCAGTC
CTTGTCCTGACAGAATGCCCCTACCATCACCCACTGAGTCTAGGCACAGCCTCTCCATC
CCTCCTGTCTCCAGCCCTCCGGAGCAGAAAGTGGGTCTTTATCGAAGACAAACTGAACT
TCAAGACAAAAGTGAATTTTCAGATGTGGACAAGCTAGCTTTTAAGGATAATGAGGAGT
TTGAATCATCTTTTGAATCTGCAGGGAACATGCCAAGGCAGTTGGAAATGGGCGGGCTT
TCTCCTGCCGGGGATATGTCTCATGTGGACGCTGCTGCAGCTGCTGTGCCCCTCTCATA
TCAGCACCCAAGTGTAGATCAGAAACAAATTGAAGAACAAAAGGAAGAAGAAAAAATAC
GGGAACAGCAAGTGAAAGAACGAAGGCAGAGAGAAGAAAGAAGGCAGAGTAACCTACAA
GAAGTTTTAGAAAGGGAACGAAGAGAACTAGAAAAACTGTATCAGGAAAGGAAGATGAT
TGAAGAATCACTGAAGATTAAAATAAAAAAGGAATTAGAAATGGAAAATGAATTAGAAA
TGAGTAATCAAGAAATAAAAGACAAATCTGCTCACAGTGAAAATCCTTTAGAGAAATAC
ATGAAAATCATCCAGCAGGAGCAAGACCAGGAGTCGGCAGATAAGAGCTCAAAAAAGAT
GGTCCAAGAAGGCTCCCTAGTGGACACGCTGCAATCTAGTGACAAAGTCGAAAGTTTAA
CAGGCTTTTCTCATGAAGAACTAGACGACTCTTGGTAA
Sequence CWU 1
1
27121DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 1gacctggacc gtgtccttac c 21221DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
2cttccccagt tccaggttct t 21320DNAArtificial SequenceDescription of
Artificial Sequence Synthetic primer 3aggacctgga ccgtgtcctt
20420DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 4tataggtccg gtggacaggg 20515DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
5ggccatcctg ccccc 15620DNAArtificial SequenceDescription of
Artificial Sequence Synthetic primer 6gagcagtcca ggtcagccag
20720DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 7ctggaccgtg tccttaccgt 20820DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
8gcagcccagg attgaactgt 20923DNAArtificial SequenceDescription of
Artificial Sequence Synthetic primer 9tggatcgaat tctcactctc aca
231021DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 10gccaagcaat ctgcgtattt g 211125DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
11tggtagaaga cttggatcga attct 251223DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
12tctcccggat tatttcttca aca 231323DNAArtificial SequenceDescription
of Artificial Sequence Synthetic primer 13gctcttcaat acagccctga tca
231424DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 14acttggatcg aattctcact ctca 241523DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
15tggatcgaat tctcactctc aca 231625DNAArtificial SequenceDescription
of Artificial Sequence Synthetic primer 16gcaaagcctg aattttcttg
aataa 251724DNAArtificial SequenceDescription of Artificial
Sequence Synthetic primer 17agggtgcatc aactcatgaa ttag
241824DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 18acttggatcg aattctcact ctca 24192850DNAArtificial
SequenceDescription of Artificial Sequence Synthetic polynucleotide
19atgggcgccc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc
60tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc
120ccagagcccg gccagcagga gcagttggtc ttcggcagcg gggatgctgt
ggagctgagc 180tgtcccccgc ccgggggtgg tcccatgggg cccactgtct
gggtcaagga tggcacaggg 240ctggtgccct cggagcgtgt cctggtgggg
ccccagcggc tgcaggtgct gaatgcctcc 300cacgaggact ccggggccta
cagctgccgg cagcggctca cgcagcgcgt actgtgccac 360ttcagtgtgc
gggtgacaga cgctccatcc tcgggagatg acgaagacgg ggaggacgag
420gctgaggaca caggtgtgga cacaggggcc ccttactgga cacggcccga
gcggatggac 480aagaagctgc tggccgtgcc ggccgccaac accgtccgct
tccgctgccc agccgctggc 540aaccccactc cctccatctc ctggctgaag
aacggcaggg agttccgcgg cgagcaccgc 600attggaggca tcaagctgcg
gcatcagcag tggagcctgg tcatggaaag cgtggtgccc 660tcggaccgcg
gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat ccggcagacg
720tacacgctgg acgtgctgga gcgctccccg caccggccca tcctgcaggc
ggggctgccg 780gccaaccaga cggcggtgct gggcagcgac gtggagttcc
actgcaaggt gtacagtgac 840gcacagcccc acatccagtg gctcaagcac
gtggaggtga atggcagcaa ggtgggcccg 900gacggcacac cctacgttac
cgtgctcaag acggcgggcg ctaacaccac cgacaaggag 960ctagaggttc
tctccttgca caacgtcacc tttgaggacg ccggggagta cacctgcctg
1020gcgggcaatt ctattgggtt ttctcatcac tctgcgtggc tggtggtgct
gccagccgag 1080gaggagctgg tggaggctga cgaggcgggc agtgtgtatg
caggcatcct cagctacggg 1140gtgggcttct tcctgttcat cctggtggtg
gcggctgtga cgctctgccg cctgcgcagc 1200ccccccaaga aaggcctggg
ctcccccacc gtgcacaaga tctcccgctt cccgctcaag 1260cgacaggtgt
ccctggagtc caacgcgtcc atgagctcca acacaccact ggtgcgcatc
1320gcaaggctgt cctcagggga gggccccacg ctggccaatg tctccgagct
cgagctgcct 1380gccgacccca aatgggagct gtctcgggcc cggctgaccc
tgggcaagcc ccttggggag 1440ggctgcttcg gccaggtggt catggcggag
gccatcggca ttgacaagga ccgggccgcc 1500aagcctgtca ccgtagccgt
gaagatgctg aaagacgatg ccactgacaa ggacctgtcg 1560gacctggtgt
ctgagatgga gatgatgaag atgatcggga aacacaaaaa catcatcaac
1620ctgctgggcg cctgcacgca gggcgggccc ctgtacgtgc tggtggagta
cgcggccaag 1680ggtaacctgc gggagtttct gcgggcgcgg cggcccccgg
gcctggacta ctccttcgac 1740acctgcaagc cgcccgagga gcagctcacc
ttcaaggacc tggtgtcctg tgcctaccag 1800gtggcccggg gcatggagta
cttggcctcc cagaagtgca tccacaggga cctggctgcc 1860cgcaatgtgc
tggtgaccga ggacaacgtg atgaagatcg cagacttcgg gctggcccgg
1920gacgtgcaca acctcgacta ctacaagaag acgaccaacg gccggctgcc
cgtgaagtgg 1980atggcgcctg aggccttgtt tgaccgagtc tacactcacc
agagtgacgt ctggtccttt 2040ggggtcctgc tctgggagat cttcacgctg
gggggctccc cgtaccccgg catccctgtg 2100gaggagctct tcaagctgct
gaaggagggc caccgcatgg acaagcccgc caactgcaca 2160cacgacctgt
acatgatcat gcgggagtgc tggcatgccg cgccctccca gaggcccacc
2220ttcaagcagc tggtggagga cctggaccgt gtccttaccg tgacgtccac
cgacgtaaag 2280gcgacacagg aggagaaccg ggagctgagg agcaggtgtg
aggagctcca cgggaagaac 2340ctggaactgg ggaagatcat ggacaggttc
gaagaggttg tgtaccaggc catggaggaa 2400gttcagaagc agaaggaact
ttccaaagct gaaatccaga aagttctaaa agaaaaagac 2460caacttacca
cagatctgaa ctccatggag aagtccttct ccgacctctt caagcgtttt
2520gagaaacaga aagaggtgat cgagggctac cgcaagaacg aagagtcact
gaagaagtgc 2580gtggaggatt acctggcaag gatcacccag gagggccaga
ggtaccaagc cctgaaggcc 2640cacgcggagg agaagctgca gctggcaaac
gaggagatcg cccaggtccg gagcaaggcc 2700caggcggaag cgttggccct
ccaggccagc ctgaggaagg agcagatgcg catccagtcg 2760ctggagaaga
cagtggagca gaagactaaa gagaacgagg agctgaccag gatctgcgac
2820gacctcatct ccaagatgga gaagatctga 2850202955DNAArtificial
SequenceDescription of Artificial Sequence Synthetic polynucleotide
20atgggcgccc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc
60tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc
120ccagagcccg gccagcagga gcagttggtc ttcggcagcg gggatgctgt
ggagctgagc 180tgtcccccgc ccgggggtgg tcccatgggg cccactgtct
gggtcaagga tggcacaggg 240ctggtgccct cggagcgtgt cctggtgggg
ccccagcggc tgcaggtgct gaatgcctcc 300cacgaggact ccggggccta
cagctgccgg cagcggctca cgcagcgcgt actgtgccac 360ttcagtgtgc
gggtgacaga cgctccatcc tcgggagatg acgaagacgg ggaggacgag
420gctgaggaca caggtgtgga cacaggggcc ccttactgga cacggcccga
gcggatggac 480aagaagctgc tggccgtgcc ggccgccaac accgtccgct
tccgctgccc agccgctggc 540aaccccactc cctccatctc ctggctgaag
aacggcaggg agttccgcgg cgagcaccgc 600attggaggca tcaagctgcg
gcatcagcag tggagcctgg tcatggaaag cgtggtgccc 660tcggaccgcg
gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat ccggcagacg
720tacacgctgg acgtgctgga gcgctccccg caccggccca tcctgcaggc
ggggctgccg 780gccaaccaga cggcggtgct gggcagcgac gtggagttcc
actgcaaggt gtacagtgac 840gcacagcccc acatccagtg gctcaagcac
gtggaggtga atggcagcaa ggtgggcccg 900gacggcacac cctacgttac
cgtgctcaag acggcgggcg ctaacaccac cgacaaggag 960ctagaggttc
tctccttgca caacgtcacc tttgaggacg ccggggagta cacctgcctg
1020gcgggcaatt ctattgggtt ttctcatcac tctgcgtggc tggtggtgct
gccagccgag 1080gaggagctgg tggaggctga cgaggcgggc agtgtgtatg
caggcatcct cagctacggg 1140gtgggcttct tcctgttcat cctggtggtg
gcggctgtga cgctctgccg cctgcgcagc 1200ccccccaaga aaggcctggg
ctcccccacc gtgcacaaga tctcccgctt cccgctcaag 1260cgacaggtgt
ccctggagtc caacgcgtcc atgagctcca acacaccact ggtgcgcatc
1320gcaaggctgt cctcagggga gggccccacg ctggccaatg tctccgagct
cgagctgcct 1380gccgacccca aatgggagct gtctcgggcc cggctgaccc
tgggcaagcc ccttggggag 1440ggctgcttcg gccaggtggt catggcggag
gccatcggca ttgacaagga ccgggccgcc 1500aagcctgtca ccgtagccgt
gaagatgctg aaagacgatg ccactgacaa ggacctgtcg 1560gacctggtgt
ctgagatgga gatgatgaag atgatcggga aacacaaaaa catcatcaac
1620ctgctgggcg cctgcacgca gggcgggccc ctgtacgtgc tggtggagta
cgcggccaag 1680ggtaacctgc gggagtttct gcgggcgcgg cggcccccgg
gcctggacta ctccttcgac 1740acctgcaagc cgcccgagga gcagctcacc
ttcaaggacc tggtgtcctg tgcctaccag 1800gtggcccggg gcatggagta
cttggcctcc cagaagtgca tccacaggga cctggctgcc 1860cgcaatgtgc
tggtgaccga ggacaacgtg atgaagatcg cagacttcgg gctggcccgg
1920gacgtgcaca acctcgacta ctacaagaag acgaccaacg gccggctgcc
cgtgaagtgg 1980atggcgcctg aggccttgtt tgaccgagtc tacactcacc
agagtgacgt ctggtccttt 2040ggggtcctgc tctgggagat cttcacgctg
gggggctccc cgtaccccgg catccctgtg 2100gaggagctct tcaagctgct
gaaggagggc caccgcatgg acaagcccgc caactgcaca 2160cacgacctgt
acatgatcat gcgggagtgc tggcatgccg cgccctccca gaggcccacc
2220ttcaagcagc tggtggagga cctggaccgt gtccttaccg tgacgtccac
cgacgtgcca 2280ggcccacccc caggtgttcc cgcgcctggg ggcccacccc
tgtccaccgg acctatagtg 2340gacctgctcc agtacagcca gaaggacctg
gatgcagtgg taaaggcgac acaggaggag 2400aaccgggagc tgaggagcag
gtgtgaggag ctccacggga agaacctgga actggggaag 2460atcatggaca
ggttcgaaga ggttgtgtac caggccatgg aggaagttca gaagcagaag
2520gaactttcca aagctgaaat ccagaaagtt ctaaaagaaa aagaccaact
taccacagat 2580ctgaactcca tggagaagtc cttctccgac ctcttcaagc
gttttgagaa acagaaagag 2640gtgatcgagg gctaccgcaa gaacgaagag
tcactgaaga agtgcgtgga ggattacctg 2700gcaaggatca cccaggaggg
ccagaggtac caagccctga aggcccacgc ggaggagaag 2760ctgcagctgg
caaacgagga gatcgcccag gtccggagca aggcccaggc ggaagcgttg
2820gccctccagg ccagcctgag gaaggagcag atgcgcatcc agtcgctgga
gaagacagtg 2880gagcagaaga ctaaagagaa cgaggagctg accaggatct
gcgacgacct catctccaag 2940atggagaaga tctga 2955214462DNAArtificial
SequenceDescription of Artificial Sequence Synthetic polynucleotide
21atgggcgccc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc
60tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc
120ccagagcccg gccagcagga gcagttggtc ttcggcagcg gggatgctgt
ggagctgagc 180tgtcccccgc ccgggggtgg tcccatgggg cccactgtct
gggtcaagga tggcacaggg 240ctggtgccct cggagcgtgt cctggtgggg
ccccagcggc tgcaggtgct gaatgcctcc 300cacgaggact ccggggccta
cagctgccgg cagcggctca cgcagcgcgt actgtgccac 360ttcagtgtgc
gggtgacaga cgctccatcc tcgggagatg acgaagacgg ggaggacgag
420gctgaggaca caggtgtgga cacaggggcc ccttactgga cacggcccga
gcggatggac 480aagaagctgc tggccgtgcc ggccgccaac accgtccgct
tccgctgccc agccgctggc 540aaccccactc cctccatctc ctggctgaag
aacggcaggg agttccgcgg cgagcaccgc 600attggaggca tcaagctgcg
gcatcagcag tggagcctgg tcatggaaag cgtggtgccc 660tcggaccgcg
gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat ccggcagacg
720tacacgctgg acgtgctgga gcgctccccg caccggccca tcctgcaggc
ggggctgccg 780gccaaccaga cggcggtgct gggcagcgac gtggagttcc
actgcaaggt gtacagtgac 840gcacagcccc acatccagtg gctcaagcac
gtggaggtga atggcagcaa ggtgggcccg 900gacggcacac cctacgttac
cgtgctcaag acggcgggcg ctaacaccac cgacaaggag 960ctagaggttc
tctccttgca caacgtcacc tttgaggacg ccggggagta cacctgcctg
1020gcgggcaatt ctattgggtt ttctcatcac tctgcgtggc tggtggtgct
gccagccgag 1080gaggagctgg tggaggctga cgaggcgggc agtgtgtatg
caggcatcct cagctacggg 1140gtgggcttct tcctgttcat cctggtggtg
gcggctgtga cgctctgccg cctgcgcagc 1200ccccccaaga aaggcctggg
ctcccccacc gtgcacaaga tctcccgctt cccgctcaag 1260cgacaggtgt
ccctggagtc caacgcgtcc atgagctcca acacaccact ggtgcgcatc
1320gcaaggctgt cctcagggga gggccccacg ctggccaatg tctccgagct
cgagctgcct 1380gccgacccca aatgggagct gtctcgggcc cggctgaccc
tgggcaagcc ccttggggag 1440ggctgcttcg gccaggtggt catggcggag
gccatcggca ttgacaagga ccgggccgcc 1500aagcctgtca ccgtagccgt
gaagatgctg aaagacgatg ccactgacaa ggacctgtcg 1560gacctggtgt
ctgagatgga gatgatgaag atgatcggga aacacaaaaa catcatcaac
1620ctgctgggcg cctgcacgca gggcgggccc ctgtacgtgc tggtggagta
cgcggccaag 1680ggtaacctgc gggagtttct gcgggcgcgg cggcccccgg
gcctggacta ctccttcgac 1740acctgcaagc cgcccgagga gcagctcacc
ttcaaggacc tggtgtcctg tgcctaccag 1800gtggcccggg gcatggagta
cttggcctcc cagaagtgca tccacaggga cctggctgcc 1860cgcaatgtgc
tggtgaccga ggacaacgtg atgaagatcg cagacttcgg gctggcccgg
1920gacgtgcaca acctcgacta ctacaagaag acgaccaacg gccggctgcc
cgtgaagtgg 1980atggcgcctg aggccttgtt tgaccgagtc tacactcacc
agagtgacgt ctggtccttt 2040ggggtcctgc tctgggagat cttcacgctg
gggggctccc cgtaccccgg catccctgtg 2100gaggagctct tcaagctgct
gaaggagggc caccgcatgg acaagcccgc caactgcaca 2160cacgacctgt
acatgatcat gcgggagtgc tggcatgccg cgccctccca gaggcccacc
2220ttcaagcagc tggtggagga cctggaccgt gtccttaccg tgacgtccac
cgacgtgagt 2280gctggctctg gcctggtgcc acccgcctat gcccctcccc
ctgccgtccc cggccatcct 2340gccccccaga gtgctgaggt gtggggcggg
cctttctggc ccaggtgccc tggctgacct 2400ggactgctca agctcttccc
agagcccagg aagttctgag aaccaaatgg tgtctccagg 2460aaaagtgtct
ggcagccctg agcaagccgt ggaggaaaac cttagttcct attccttaga
2520cagaagagtg acacccgcct ctgagaccct agaagaccct tgcaggacag
agtcccagca 2580caaagcggag actccgcacg gagccgagga agaatgcaaa
gcggagactc cgcacggagc 2640cgaggaggaa tgccggcacg gtggggtctg
tgctcccgca gcagtggcca cttcgcctcc 2700tggtgcaatc cctaaggaag
cctgcggagg agcacccctg cagggtctgc ctggcgaagc 2760cctgggctgc
cctgcgggtg tgggcacccc cgtgccagca gatggcactc agacccttac
2820ctgtgcacac acctctgctc ctgagagcac agccccaacc aaccacctgg
tggctggcag 2880ggccatgacc ctgagtcctc aggaagaagt ggctgcaggc
caaatggcca gctcctcgag 2940gagcggacct gtaaaactag aatttgatgt
atctgatggc gccaccagca aaagggcacc 3000cccaccaagg agactgggag
agaggtccgg cctcaagcct cccttgagga aagcagcagt 3060gaggcagcaa
aaggccccgc aggaggtgga ggaggacgac ggtaggagcg gagcaggaga
3120ggaccccccc atgccagctt ctcggggctc ttaccacctc gactgggaca
aaatggatga 3180cccaaacttc atcccgttcg gaggtgacac caagtctggt
tgcagtgagg cccagccccc 3240agaaagccct gagaccaggc tgggccagcc
agcggctgaa cagttgcatg ctgggcctgc 3300cacggaggag ccaggtccct
gtctgagcca gcagctgcat tcagcctcag cggaggacac 3360gcctgtggtg
cagttggcag ccgagacccc aacagcagag agcaaggaga gagccttgaa
3420ctctgccagc acctcgcttc ccacaagctg tccaggcagt gagccagtgc
ccacccatca 3480gcaggggcag cctgccttgg agctgaaaga ggagagcttc
agagaccccg ctgaggttct 3540aggcacgggc gcggaggtgg attacctgga
gcagtttgga acttcctcgt ttaaggagtc 3600ggccttgagg aagcagtcct
tatacctcaa gttcgacccc ctcctgaggg acagtcctgg 3660tagaccagtg
cccgtggcca ccgagaccag cagcatgcac ggtgcaaatg agactccctc
3720aggacgtccg cgggaagcca agcttgtgga gttcgatttc ttgggagcac
tggacattcc 3780tgtgccaggc ccacccccag gtgttcccgc gcctgggggc
ccacccctgt ccaccggacc 3840tatagtggac ctgctccagt acagccagaa
ggacctggat gcagtggtaa aggcgacaca 3900ggaggagaac cgggagctga
ggagcaggtg tgaggagctc cacgggaaga acctggaact 3960ggggaagatc
atggacaggt tcgaagaggt tgtgtaccag gccatggagg aagttcagaa
4020gcagaaggaa ctttccaaag ctgaaatcca gaaagttcta aaagaaaaag
accaacttac 4080cacagatctg aactccatgg agaagtcctt ctccgacctc
ttcaagcgtt ttgagaaaca 4140gaaagaggtg atcgagggct accgcaagaa
cgaagagtca ctgaagaagt gcgtggagga 4200ttacctggca aggatcaccc
aggagggcca gaggtaccaa gccctgaagg cccacgcgga 4260ggagaagctg
cagctggcaa acgaggagat cgcccaggtc cggagcaagg cccaggcgga
4320agcgttggcc ctccaggcca gcctgaggaa ggagcagatg cgcatccagt
cgctggagaa 4380gacagtggag cagaagacta aagagaacga ggagctgacc
aggatctgcg acgacctcat 4440ctccaagatg gagaagatct ga
4462223765DNAArtificial SequenceDescription of Artificial Sequence
Synthetic polynucleotide 22atgggcgccc ctgcctgcgc cctcgcgctc
tgcgtggccg tggccatcgt ggccggcgcc 60tcctcggagt ccttggggac ggagcagcgc
gtcgtggggc gagcggcaga agtcccgggc 120ccagagcccg gccagcagga
gcagttggtc ttcggcagcg gggatgctgt ggagctgagc 180tgtcccccgc
ccgggggtgg tcccatgggg cccactgtct gggtcaagga tggcacaggg
240ctggtgccct cggagcgtgt cctggtgggg ccccagcggc tgcaggtgct
gaatgcctcc 300cacgaggact ccggggccta cagctgccgg cagcggctca
cgcagcgcgt actgtgccac 360ttcagtgtgc gggtgacaga cgctccatcc
tcgggagatg acgaagacgg ggaggacgag 420gctgaggaca caggtgtgga
cacaggggcc ccttactgga cacggcccga gcggatggac 480aagaagctgc
tggccgtgcc ggccgccaac accgtccgct tccgctgccc agccgctggc
540aaccccactc cctccatctc ctggctgaag aacggcaggg agttccgcgg
cgagcaccgc 600attggaggca tcaagctgcg gcatcagcag tggagcctgg
tcatggaaag cgtggtgccc 660tcggaccgcg gcaactacac ctgcgtcgtg
gagaacaagt ttggcagcat ccggcagacg 720tacacgctgg acgtgctgga
gcgctccccg caccggccca tcctgcaggc ggggctgccg 780gccaaccaga
cggcggtgct gggcagcgac gtggagttcc actgcaaggt gtacagtgac
840gcacagcccc acatccagtg gctcaagcac gtggaggtga atggcagcaa
ggtgggcccg 900gacggcacac cctacgttac cgtgctcaag tcctggatca
gtgagagtgt ggaggccgac 960gtgcgcctcc gcctggccaa tgtgtcggag
cgggacgggg gcgagtacct ctgtcgagcc 1020accaatttca taggcgtggc
cgagaaggcc ttttggctga gcgttcacgg gccccgagca 1080gccgaggagg
agctggtgga ggctgacgag gcgggcagtg tgtatgcagg catcctcagc
1140tacggggtgg gcttcttcct gttcatcctg gtggtggcgg ctgtgacgct
ctgccgcctg 1200cgcagccccc ccaagaaagg cctgggctcc cccaccgtgc
acaagatctc ccgcttcccg 1260ctcaagcgac aggtgtccct ggagtccaac
gcgtccatga gctccaacac accactggtg 1320cgcatcgcaa ggctgtcctc
aggggagggc cccacgctgg ccaatgtctc cgagctcgag 1380ctgcctgccg
accccaaatg ggagctgtct cgggcccggc tgaccctggg caagcccctt
1440ggggagggct gcttcggcca ggtggtcatg gcggaggcca tcggcattga
caaggaccgg 1500gccgccaagc ctgtcaccgt agccgtgaag atgctgaaag
acgatgccac tgacaaggac 1560ctgtcggacc tggtgtctga gatggagatg
atgaagatga tcgggaaaca caaaaacatc 1620atcaacctgc tgggcgcctg
cacgcagggc gggcccctgt acgtgctggt ggagtacgcg 1680gccaagggta
acctgcggga gtttctgcgg gcgcggcggc ccccgggcct ggactactcc
1740ttcgacacct gcaagccgcc cgaggagcag ctcaccttca aggacctggt
gtcctgtgcc 1800taccaggtgg cccggggcat ggagtacttg gcctcccaga
agtgcatcca cagggacctg 1860gctgcccgca atgtgctggt gaccgaggac
aacgtgatga agatcgcaga cttcgggctg 1920gcccgggacg tgcacaacct
cgactactac aagaagacga ccaacggccg gctgcccgtg
1980aagtggatgg cgcctgaggc cttgtttgac cgagtctaca ctcaccagag
tgacgtctgg 2040tcctttgggg tcctgctctg ggagatcttc acgctggggg
gctccccgta ccccggcatc 2100cctgtggagg agctcttcaa gctgctgaag
gagggccacc gcatggacaa gcccgccaac 2160tgcacacacg acctgtacat
gatcatgcgg gagtgctggc atgccgcgcc ctcccagagg 2220cccaccttca
agcagctggt ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac
2280aatgttatgg aacagttcaa tcctgggctg cgaaatttaa taaacctggg
gaaaaattat 2340gagaaagctg taaacgctat gatcctggca ggaaaagcct
actacgatgg agtggccaag 2400atcggtgaga ttgccactgg gtcccccgtg
tcaactgaac tgggacatgt cctcatagag 2460atttcaagta cccacaagaa
actcaacgag agtcttgatg aaaattttaa aaaattccac 2520aaagagatta
tccatgagct ggagaagaag atagaacttg acgtgaaata tatgaacgca
2580actctaaaaa gataccaaac agaacacaag aataaattag agtctttgga
gaaatcccaa 2640gctgagttga agaagatcag aaggaaaagc caaggaagcc
gaaacgcact caaatatgaa 2700cacaaagaaa ttgagtatgt ggagaccgtt
acttctcgtc agagtgaaat ccagaaattc 2760attgcagatg gttgcaaaga
ggctctgctt gaagagaaga ggcgcttctg ctttctggtt 2820gataagcact
gtggctttgc aaaccacata cattattatc acttacagtc tgcagaacta
2880ctgaattcca agctgcctcg gtggcaggag acctgtgttg atgccatcaa
agtgccagag 2940aaaatcatga atatgatcga agaaataaag accccagcct
ctacccccgt gtctggaact 3000cctcaggctt cacccatgat cgagagaagc
aatgtggtta ggaaagatta cgacaccctt 3060tctaaatgct caccaaagat
gccccccgct ccttcaggca gagcatatac cagtcccttg 3120atcgatatgt
ttaataaccc agccacggct gccccgaatt cacaaagggt aaataattca
3180acaggtactt ccgaagatcc cagtttacag cgatcagttt cggttgcaac
gggactgaac 3240atgatgaaga agcagaaagt gaagaccatc ttcccgcaca
ctgcgggctc caacaagacc 3300ttactcagct ttgcacaggg agatgtcatc
acgctgctca tccccgagga gaaggatggc 3360tggctctatg gagaacacga
cgtgtccaag gcgaggggtt ggttcccgtc gtcgtacacg 3420aagttgctgg
aagaaaatga gacagaagca gtgaccgtgc ccacgccaag ccccacacca
3480gtgagaagca tcagcaccgt gaacttgtct gagaatagca gtgttgtcat
ccccccaccc 3540gactacttgg aatgcttgtc catgggggca gctgccgaca
ggagagcaga ttcggccagg 3600acgacatcca cctttaaggc cccagcgtcc
aagcccgaga ccgcggctcc taacgatgcc 3660aacgggactg caaagccgcc
ttttctcagc ggagaaaacc cctttgccac tgtgaaactc 3720cgcccgactg
tgacgaatga tcgctcggca cccatcattc gatga 3765234989DNAArtificial
SequenceDescription of Artificial Sequence Synthetic polynucleotide
23atggtcagct ggggtcgttt catctgcctg gtcgtggtca ccatggcaac cttgtccctg
60gcccggccct ccttcagttt agttgaggat accacattag agccagaaga gccaccaacc
120aaataccaaa tctctcaacc agaagtgtac gtggctgcgc caggggagtc
gctagaggtg 180cgctgcctgt tgaaagatgc cgccgtgatc agttggacta
aggatggggt gcacttgggg 240cccaacaata ggacagtgct tattggggag
tacttgcaga taaagggcgc cacgcctaga 300gactccggcc tctatgcttg
tactgccagt aggactgtag acagtgaaac ttggtacttc 360atggtgaatg
tcacagatgc catctcatcc ggagatgatg aggatgacac cgatggtgcg
420gaagattttg tcagtgagaa cagtaacaac aagagagcac catactggac
caacacagaa 480aagatggaaa agcggctcca tgctgtgcct gcggccaaca
ctgtcaagtt tcgctgccca 540gccgggggga acccaatgcc aaccatgcgg
tggctgaaaa acgggaagga gtttaagcag 600gagcatcgca ttggaggcta
caaggtacga aaccagcact ggagcctcat tatggaaagt 660gtggtcccat
ctgacaaggg aaattatacc tgtgtagtgg agaatgaata cgggtccatc
720aatcacacgt accacctgga tgttgtggag cgatcgcctc accggcccat
cctccaagcc 780ggactgccgg caaatgcctc cacagtggtc ggaggagacg
tagagtttgt ctgcaaggtt 840tacagtgatg cccagcccca catccagtgg
atcaagcacg tggaaaagaa cggcagtaaa 900tacgggcccg acgggctgcc
ctacctcaag gttctcaagg ccgccggtgt taacaccacg 960gacaaagaga
ttgaggttct ctatattcgg aatgtaactt ttgaggacgc tggggaatat
1020acgtgcttgg cgggtaattc tattgggata tcctttcact ctgcatggtt
gacagttctg 1080ccagcgcctg gaagagaaaa ggagattaca gcttccccag
actacctgga gatagccatt 1140tactgcatag gggtcttctt aatcgcctgt
atggtggtaa cagtcatcct gtgccgaatg 1200aagaacacga ccaagaagcc
agacttcagc agccagccgg ctgtgcacaa gctgaccaaa 1260cgtatccccc
tgcggagaca ggtaacagtt tcggctgagt ccagctcctc catgaactcc
1320aacaccccgc tggtgaggat aacaacacgc ctctcttcaa cggcagacac
ccccatgctg 1380gcaggggtct ccgagtatga acttccagag gacccaaaat
gggagtttcc aagagataag 1440ctgacactgg gcaagcccct gggagaaggt
tgctttgggc aagtggtcat ggcggaagca 1500gtgggaattg acaaagacaa
gcccaaggag gcggtcaccg tggccgtgaa gatgttgaaa 1560gatgatgcca
cagagaaaga cctttctgat ctggtgtcag agatggagat gatgaagatg
1620attgggaaac acaagaatat cataaatctt cttggagcct gcacacagga
tgggcctctc 1680tatgtcatag ttgagtatgc ctctaaaggc aacctccgag
aatacctccg agcccggagg 1740ccacccggga tggagtactc ctatgacatt
aaccgtgttc ctgaggagca gatgaccttc 1800aaggacttgg tgtcatgcac
ctaccagctg gccagaggca tggagtactt ggcttcccaa 1860aaatgtattc
atcgagattt agcagccaga aatgttttgg taacagaaaa caatgtgatg
1920aaaatagcag actttggact cgccagagat atcaacaata tagactatta
caaaaagacc 1980accaatgggc ggcttccagt caagtggatg gctccagaag
ccctgtttga tagagtatac 2040actcatcaga gtgatgtctg gtccttcggg
gtgttaatgt gggagatctt cactttaggg 2100ggctcgccct acccagggat
tcccgtggag gaacttttta agctgctgaa ggaaggacac 2160agaatggata
agccagccaa ctgcaccaac gaactgtaca tgatgatgag ggactgttgg
2220catgcagtgc cctcccagag accaacgttc aagcagttgg tagaagactt
ggatcgaatt 2280ctcactctca caaccaatga gatcatggag gaaacaaata
cgcagattgc ttggccatca 2340aaactgaaga tcggagccaa atccaagaaa
gatccccata ttaaggtttc tggaaagaaa 2400gaagatgtta aagaagccaa
ggaaatgatc atgtctgtct tagacacaaa aagcaatcga 2460gtcacactga
agatggatgt ttcacataca gaacattcac atgtaatcgg caaaggtggc
2520aacaatatta aaaaagtgat ggaagaaacc ggatgccata tccactttcc
agattccaac 2580aggaataacc aagcagaaaa aagcaaccag gtatctatag
cgggacaacc agcaggagta 2640gaatctgccc gagttagaat tcgggagctg
cttcctttgg tgctgatgtt tgagctacca 2700attgctggaa ttcttcaacc
ggttcctgat cctaattccc cctctattca gcatatatca 2760caaacgtaca
atatttcagt atcatttaaa cagcgttccc gaatgtatgg tgctactgtc
2820atagtacgag ggtctcagaa taacactagt gctgtgaagg aaggaactgc
catgctgtta 2880gaacatcttg ctgggagctt agcatcagct attcctgtga
gcacacaact agatattgca 2940gctcaacatc atctctttat gatgggtcga
aatgggagca acatcaaaca tatcatgcag 3000agaacaggtg ctcagatcca
ctttcctgat cccagtaatc cacaaaagaa atctaccgtc 3060tacctccagg
gcaccattga gtctgtctgt cttgcaaggc aatatctcat gggttgtctt
3120cctcttgtgt tgatgtttga tatgaaggaa gaaattgaag tagatccaca
attcattgcg 3180cagttgatgg aacagcttga tgtcttcatc agtattaaac
caaagcccaa acagccaagc 3240aagtctgtga ttgtgaaaag tgttgagcga
aatgccttaa atatgtatga agcaaggaaa 3300tgtctcctcg gacttgaaag
cagtggggtt accatagcaa ccagtccatc cccagcatcc 3360tgccctgccg
gcctggcatg tcccagcctg gatatcttag cttcagcagg ccttggactc
3420actggactag gtcttttggg acccaccacc ttatctctga acacttcaac
aaccccaaac 3480tcactcttga atgctcttaa tagctcagtc agtcctttgc
aaagtccaag ttctggtaca 3540cccagcccca cattatgggc acccccactt
gctaatactt caagtgccac aggtttttct 3600gctataccac accttatgat
tccatctact gcccaagcca cattaactaa tattttgttg 3660tctggagtgc
ccacctatgg gcacacagct ccatctcccc ctcctggctt gactcctgtt
3720gatgtccata tcaacagtat gcagaccgaa ggcaaaaaaa tctctgctgc
tttaaatgga 3780catgcacagt ctccagatat aaaatatggt gcaatatcca
cttcatcact tggagaaaaa 3840gtgctgagtg caaatcacgg ggatccgtcc
atccagacaa gtgggtctga gcagacatct 3900cccaaatcaa gccccactga
aggttgtaat gatgcttttg ttgaagtagg catgcctcga 3960agtccttccc
attctgggaa tgctggtgac ttgaaacaga tgatgtgtcc ctccaaggtt
4020tcctgtgcca aaaggcagac agtggaacta ttgcaaggca cgaaaaactc
acacttacac 4080agcactgaca ggttgctctc agaccctgaa ctgagtgcta
ccgaaagccc tttggctgac 4140aagaaggctc cagggagtga gcgcgctgca
gagagggcag cagctgccca gcaaaactcc 4200gaaagggccc accttgctcc
acggtcatca tatgtcaaca tgcaggcatt tgactatgaa 4260cagaagaagc
tattagccac caaagctatg ttaaagaaac cagtggtgac ggaggtcaga
4320acgcccacaa atacctggag tggcctgggt ttttctaaat ccatgccagc
tgaaactatc 4380aaggagttga gaagggccaa tcatgtgtcc tataagccca
caatgacaac cacttatgag 4440ggctcatcca tgtccctttc acggtccaac
agtcgtgagc acttgggagg tggaagcgaa 4500tctgataact ggagagaccg
aaatggaatt ggacctggaa gtcatagtga atttgcagct 4560tctattggca
gccctaagcg taaacaaaac aaatcaacgg aacactatct cagcagtagc
4620aattacatgg actgcatttc ctcgctgaca ggaagcaatg gctgtaactt
aaatagctct 4680ttcaaaggtt ctgacctccc tgagctcttc agcaaactgg
gcctgggcaa atacacagat 4740gttttccagc aacaagagat cgatcttcag
acattcctca ctctcacaga tcaggatctg 4800aaggagctgg gaataactac
ttttggtgcc aggaggaaaa tgctgcttgc aatttcagaa 4860ctaaataaaa
accgaagaaa gctttttgaa tcgccaaatg cacgcacctc tttcctggaa
4920ggtggagcga gtggaaggct accccgtcag tatcactcag acattgctag
tgtcagtggc 4980cgctggtag 4989245109DNAArtificial
SequenceDescription of Artificial Sequence Synthetic polynucleotide
24atggtcagct ggggtcgttt catctgcctg gtcgtggtca ccatggcaac cttgtccctg
60gcccggccct ccttcagttt agttgaggat accacattag agccagaaga gccaccaacc
120aaataccaaa tctctcaacc agaagtgtac gtggctgcgc caggggagtc
gctagaggtg 180cgctgcctgt tgaaagatgc cgccgtgatc agttggacta
aggatggggt gcacttgggg 240cccaacaata ggacagtgct tattggggag
tacttgcaga taaagggcgc cacgcctaga 300gactccggcc tctatgcttg
tactgccagt aggactgtag acagtgaaac ttggtacttc 360atggtgaatg
tcacagatgc catctcatcc ggagatgatg aggatgacac cgatggtgcg
420gaagattttg tcagtgagaa cagtaacaac aagagagcac catactggac
caacacagaa 480aagatggaaa agcggctcca tgctgtgcct gcggccaaca
ctgtcaagtt tcgctgccca 540gccgggggga acccaatgcc aaccatgcgg
tggctgaaaa acgggaagga gtttaagcag 600gagcatcgca ttggaggcta
caaggtacga aaccagcact ggagcctcat tatggaaagt 660gtggtcccat
ctgacaaggg aaattatacc tgtgtagtgg agaatgaata cgggtccatc
720aatcacacgt accacctgga tgttgtggag cgatcgcctc accggcccat
cctccaagcc 780ggactgccgg caaatgcctc cacagtggtc ggaggagacg
tagagtttgt ctgcaaggtt 840tacagtgatg cccagcccca catccagtgg
atcaagcacg tggaaaagaa cggcagtaaa 900tacgggcccg acgggctgcc
ctacctcaag gttctcaagg ccgccggtgt taacaccacg 960gacaaagaga
ttgaggttct ctatattcgg aatgtaactt ttgaggacgc tggggaatat
1020acgtgcttgg cgggtaattc tattgggata tcctttcact ctgcatggtt
gacagttctg 1080ccagcgcctg gaagagaaaa ggagattaca gcttccccag
actacctgga gatagccatt 1140tactgcatag gggtcttctt aatcgcctgt
atggtggtaa cagtcatcct gtgccgaatg 1200aagaacacga ccaagaagcc
agacttcagc agccagccgg ctgtgcacaa gctgaccaaa 1260cgtatccccc
tgcggagaca ggtaacagtt tcggctgagt ccagctcctc catgaactcc
1320aacaccccgc tggtgaggat aacaacacgc ctctcttcaa cggcagacac
ccccatgctg 1380gcaggggtct ccgagtatga acttccagag gacccaaaat
gggagtttcc aagagataag 1440ctgacactgg gcaagcccct gggagaaggt
tgctttgggc aagtggtcat ggcggaagca 1500gtgggaattg acaaagacaa
gcccaaggag gcggtcaccg tggccgtgaa gatgttgaaa 1560gatgatgcca
cagagaaaga cctttctgat ctggtgtcag agatggagat gatgaagatg
1620attgggaaac acaagaatat cataaatctt cttggagcct gcacacagga
tgggcctctc 1680tatgtcatag ttgagtatgc ctctaaaggc aacctccgag
aatacctccg agcccggagg 1740ccacccggga tggagtactc ctatgacatt
aaccgtgttc ctgaggagca gatgaccttc 1800aaggacttgg tgtcatgcac
ctaccagctg gccagaggca tggagtactt ggcttcccaa 1860aaatgtattc
atcgagattt agcagccaga aatgttttgg taacagaaaa caatgtgatg
1920aaaatagcag actttggact cgccagagat atcaacaata tagactatta
caaaaagacc 1980accaatgggc ggcttccagt caagtggatg gctccagaag
ccctgtttga tagagtatac 2040actcatcaga gtgatgtctg gtccttcggg
gtgttaatgt gggagatctt cactttaggg 2100ggctcgccct acccagggat
tcccgtggag gaacttttta agctgctgaa ggaaggacac 2160agaatggata
agccagccaa ctgcaccaac gaactgtaca tgatgatgag ggactgttgg
2220catgcagtgc cctcccagag accaacgttc aagcagttgg tagaagactt
ggatcgaatt 2280ctcactctca caaccaatga ggagagtaga tctggagaaa
ccaacagctg tgttgaagaa 2340ataatccggg agatgacctg gcttccacca
ctttctgcta ttcaagcacc tggcaaagtg 2400gaaccaacca aatttccatt
tccaaataag gactctcagc ttgtatcctc tggacacaat 2460aatccaaaga
aaggtgatgc agagccagag agtccagaca gtggcacatc gaatacatca
2520atgctggaag atgaccttaa gctaagcagt gatgaagagg agaatgaaca
gcaggcagct 2580cagagaacgg ctctccgcgc tctctctgac agcgccgtgg
tccagcagcc caactgcaga 2640acctcggtgc cttccagcaa gggcagcagc
agcagcagca gcagcggcag cagcagctcc 2700tccagcgact cagagagcag
ctccggatct gactcggaga ccgagagcag ctccagcgag 2760agtgagggca
gcaagccccc ccacttctcc agccccgagg ctgaaccggc atcctctaac
2820aagtggcagc tggataaatg gctaaacaaa gttaatcccc acaagcctcc
tattctgatc 2880caaaatgaaa gccacgggtc agagagcaat cagtactaca
acccggtgaa agaggacgtc 2940caggactgtg ggaaagtccc cgacgtttgc
cagcccagcc tgagagagaa ggagatcaag 3000agcacttgca aggaggagca
aaggccaagg acagccaaca aggcccctgg gagtaaaggc 3060gtgaagcaga
agtccccgcc cgcggccgtg gccgtggcgg tgagcgcagc cgccccgcca
3120cccgcagtgc cctgtgcgcc cgcggagaac gcgcccgcgc ctgcccggag
gtccgcgggc 3180aagaagccca ccaggcgcac cgagaggacc tcagccgggg
acggcgccaa ctgccaccgg 3240cccgaggagc ccgcggccgc ggacgcgctg
gggacgagcg tggtggtccc cccggagccc 3300accaaaacca ggccctgtgg
caacaacaga gcgagccacc gcaaggagct gcgctcctcc 3360gtgacctgcg
agaagcgccg cacgcggggg ctaagcagga tcgtccccaa atccaaggag
3420ttcattgaga cagagtcgtc atcttcatcc tcctcctcgg actccgacct
ggagtccgag 3480caggaggagt accctctgtc caaagcacag accgtggctg
cctctgcctc ctccgggaat 3540gatcagaggc tgaaggaggc cgctgccaac
gggggcagtg gtcctagggc ccctgtaggc 3600tccatcaacg ccaggaccac
cagtgacatc gccaaggagc tggaggagca gttctacaca 3660ctggtcccct
ttggccggaa cgaacttctc tcccctctaa aggacagtga tgagatcagg
3720tctctctggg tcaaaatcga cctgaccctc ctgtccagga tcccagaaca
cctgccccag 3780gagccagggg tattgagcgc ccctgccacc aaggactctg
agagcgcacc gcccagccac 3840acctcggaca cacctgcaga aaaggctttg
ccaaaatcca agaggaaacg caagtgtgac 3900aacgaagacg actacaggga
gatcaagaag tcccagggag agaaagacag ctcttcaaga 3960ctggccacct
ccaccagtaa tactttgtct gcaaaccact gcaacatgaa catcaacagt
4020gtggcaatac caataaataa aaatgaaaaa atgcttcggt cgcccatctc
acccctctct 4080gatgcatcta aacacaaata caccagcgag gacttaactt
cttccagccg acctaatggc 4140aacagtttgt ttacttcagc ctcttccagc
aaaaagccta aggccgacag ccagctgcag 4200cctcacggcg gagacctcac
gaaagcagct cacaacaatt ctgaaaacat tcccctccac 4260aagtcacggc
cgcagacgaa gccgtggtct ccaggctcca acggccacag ggactgcaag
4320aggcagaaac ttgtcttcga tgatatgcct cgcagtgccg attattttat
gcaagaagct 4380aaacgaatga agcataaagc agatgcaatg gtggaaaagt
ttggaaaggc tttgaactat 4440gctgaagcag cattgtcgtt tatcgagtgt
ggaaatgcaa tggaacaagg ccccatggaa 4500tccaaatctc cttatacgat
gtattcagaa acagtagagc tcatcaggta tgctatgaga 4560ctaaaaaccc
actcaggccc caatgccaca ccagaagaca aacaactggc tgcattatgt
4620taccgatgcc tggccctcct gtactggcgg atgtttcgac tcaaaaggga
ccacgctgta 4680aagtattcaa aagcactaat cgactatttc aagaactcat
ctaaagccgc ccaagcccca 4740tctccgtggg gggccagtgg aaagagcact
ggaaccccat cccccatgtc tcccaacccc 4800tctcccgcca gctccgtggg
gtctcagggc agcctctcca acgccagcgc cctgtccccg 4860tcgaccatcg
tcagcatccc acagcgcatc caccagatgg cggccaacca cgtcagcatc
4920accaacagca tcctgcacag ctacgactac tgggagatgg ccgacaacct
ggccaaggaa 4980aaccgagaat tcttcaacga cctggatctg ctcatggggc
cggtcaccct gcacagcagc 5040atggagcacc tggtccagta ctcccaacag
ggcctgcact ggctgcggaa cagcgcccac 5100ctgtcatag
5109253213DNAArtificial SequenceDescription of Artificial Sequence
Synthetic polynucleotide 25atggtcagct ggggtcgttt catctgcctg
gtcgtggtca ccatggcaac cttgtccctg 60gcccggccct ccttcagttt agttgaggat
accacattag agccagaaga gccaccaacc 120aaataccaaa tctctcaacc
agaagtgtac gtggctgcgc caggggagtc gctagaggtg 180cgctgcctgt
tgaaagatgc cgccgtgatc agttggacta aggatggggt gcacttgggg
240cccaacaata ggacagtgct tattggggag tacttgcaga taaagggcgc
cacgcctaga 300gactccggcc tctatgcttg tactgccagt aggactgtag
acagtgaaac ttggtacttc 360atggtgaatg tcacagatgc catctcatcc
ggagatgatg aggatgacac cgatggtgcg 420gaagattttg tcagtgagaa
cagtaacaac aagagagcac catactggac caacacagaa 480aagatggaaa
agcggctcca tgctgtgcct gcggccaaca ctgtcaagtt tcgctgccca
540gccgggggga acccaatgcc aaccatgcgg tggctgaaaa acgggaagga
gtttaagcag 600gagcatcgca ttggaggcta caaggtacga aaccagcac
References